Document:

EX-10.8

 Exhibit 10.8 

EXECUTION COPY 
 FOIA
CONFIDENTIAL TREATMENT REQUESTED 
 Confidential Materials omitted and filed separate with the Securities and Exchange Commission

 Triple asterisks denote omissions 

LICENSE AGREEMENT 
 by and
between 
 HANMI PHARMACEUTICAL CO., LTD. 

and 
 KINEX THERAPEUTICS (HK)
LIMITED 
 and 
 KINEX
PHARMACEUTICALS, INC. (as guarantor) 
 ON 

ORASCOVERY PROGRAM 

MAINLAND CHINA TERRITORY 
  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

Confidential Materials omitted and filed separate with the Securities and Exchange Commission 

Triple asterisks denote omissions 

TABLE OF CONTENTS 
  

					
	 	  	Page	 
	 ARTICLE 1 DEFINITIONS
	  	 	2	  
		
	 ARTICLE 2 GRANT OF RIGHTS
	  	 	15	  
		
	 ARTICLE 3 INFORMATION TRANSFER; DEVELOPMENT AND COMMERCIALIZATION; REGULATORY MATTERS
	  	 	17	  
		
	 ARTICLE 4 PAYMENTS AND STATEMENTS
	  	 	25	  
		
	 ARTICLE 5 REPRESENTATIONS AND WARRANTIES
	  	 	31	  
		
	 ARTICLE 6 PATENT MATTERS
	  	 	34	  
		
	 ARTICLE 7 CONFIDENTIALITY AND PUBLICITY
	  	 	41	  
		
	 ARTICLE 8 TERM AND TERMINATION
	  	 	44	  
		
	 ARTICLE 9 INDEMNIFICATION AND INSURANCE
	  	 	48	  
		
	 ARTICLE 10 MISCELLANEOUS
	  	 	52	  

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2013
(“Effective Date”), by and among KINEX THERAPEUTICS (HK) LIMITED, a corporation organized and existing under the laws of Hong Kong and having its principal office at 11/F, AXA Centre, 151 Gloucester Road, Hong Kong
(“Kinex”), HANMI PHARMACEUTICAL CO., LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 14,Wiryeseong-daero,Songpa-gu, Seoul, 138-724 South Korea
(“Hanmi”) and KINEX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, United States,
previously known as Kinex Pharmaceuticals, LLC (“Kinex US”). 
 WITNESSETH: 

WHEREAS, Hanmi owns or Controls the Hanmi Intellectual Property and is developing Compounds for improved absorption for oral drug
dosing; 
 WHEREAS, Kinex and its Affiliates have experience in the development, marketing, promotion and sale of pharmaceutical
products and Kinex desires to obtain the exclusive right and license in the Territory to further develop and thereafter commercialize Licensed Products in the Field; and 

WHEREAS, Hanmi has previously licensed the Hanmi Intellectual Property in other territories to Kinex US; and 

WHEREAS, Hanmi desires to grant to Kinex, currently a wholly owned subsidiary of Kinex US, such exclusive right and license in the
Territory, all on the terms and conditions set forth below. 

  
 1 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 NOW, THEREFORE, in consideration of the mutual representations, warranties and
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the
respective meanings set forth below: 
 1.1 “Act” means the Drug Administration Law of the People’s Republic of China,
as amended, and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. 

1.2 “Affiliate(s)” means with respect to a Party: (a) any corporation or business entity of which more than fifty
percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a Party; (b) any corporation or business
entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general
partnership interest of a Party; (c) any corporation or business entity of which, directly or indirectly, an entity described in the immediately preceding subsection (b) controls or holds more than fifty percent (50%) (or the maximum
ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of such corporation or entity; or (d) any corporation or business entity of which a Party
has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock or general partnership interest thereof. 

1.3 “Agreement Term” has the meaning set forth in Section 8.1. 

  
 2 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.4 “Breaching Party” has the meaning set forth in Section 8.2(c). 

1.5 “Business Day” means any calendar day, except that if an activity to be performed or an event to occur falls on a,
Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may occur on the next day that is not a
Saturday, Sunday or nationally recognized holiday. 
 1.6 “Calendar Quarter” means for each Calendar Year, each of the
three (3) month periods ending on March 31, June 30, September 30 and December 31; provided, however, that (i) the first Calendar Quarter of any period specified under this Agreement shall extend from the
commencement of such period to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 

1.7 “Calendar Year” means, for the first Calendar Year, the period commencing on the Effective Date and ending on
December 31, 2013, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 

1.8 “cGMP” means current Good Manufacturing Practice. 

1.9 “Claims” has the meaning set forth in Section 9.2. 

1.10 “Clinical Studies” means any clinical studies of a Licensed Product conducted on humans. 

1.11 “Commercialize” or “Commercialization” means promotion, marketing, sale, supply, manufacture, import,
export and distribution of Licensed Products, including any educational or pre-launch activities. 

  
 3 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.12 “Commercially Reasonable Efforts” means exerting such efforts and
employing such resources as would normally be exerted or employed by a Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential. 

1.13 “Completion” means, with respect to any clinical study, the completion of treatment for the necessary number of patients
required by the applicable protocol and completion of the statistical analysis of the study data. 
 1.14 “Compound(s)”
means any and all pump inhibiting compounds discovered or developed in the Orascovery Program, including HM30181A (a P-Glycoprotein inhibitor) as diagrammed on Schedule 1.1 attached hereto, and any pharmaceutically acceptable salts,
hydrates, solvates, amides, prodrugs, metabolites, and esters of the foregoing, or mixtures or combinations of any such compounds. 
 1.15
“Control” means possession of the ability to grant the rights and licenses as provided for herein without violating the terms of any agreement or arrangement with any Third Party. 

1.16 “Copyright” means the rights granted to an author or creator of an original work fixed in any tangible medium of
expression, including without limitation, books, literary works, computer programs, and pictorial, graphic, dramatic and sculptured works, as well as derivative works and translations. 

1.17 “CSRC” means the China Securities Regulatory Commission and any successor agency having substantially the same
functions. 
 1.18 “Data” means any and all research data, pharmacology data, preclinical data, clinical data, adverse
reaction data, chemistry, manufacturing and control (“CMC”) data and/or all other similar documentation generated in connection with any Compound or any Licensed Product. 

1.19 “Develop” or “Development” means those activities undertaken with respect to any Compound or any
Licensed Product which are devoted to the progression of a potential pharmaceutical product in Clinical Studies and any other activities directed toward quality issues, publication, Regulatory Approval, formulation, production or CMC of such
Compound or Licensed Product, including any other pre-launch activities. 

  
 4 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.20 “Direct Kinex Sales” means all sales of Licensed Product by Kinex as
the result of the direct marketing and sale of Licensed Product after Regulatory Approval. 
 1.21 “Disputed Claim” has the
meaning set forth in Section 9.4(b). 
 1.22 “Dollar” or “$” means the lawful currency of the United
States. 
 1.23 “Drug Approval Application” means an application for Regulatory Approval of a Licensed Product as a
pharmaceutical product in the Territory. 
 1.24 “DRR” means the Drug Registration Regulations of the SFDA. 

1.25 “Effective Date” has the meaning set forth in the Preamble hereof. 

1.26 “Field” means the enhancement of oral absorption of any pharmaceutical preparation in humans or animals. 

1.27 “First Commercial Sale” means, with respect to any Licensed Product, the first sale to a Third Party for end use or
consumption of such Licensed Product in the Territory by Kinex, its Affiliates or sublicensees after receipt of Regulatory Approval in such Territory or, where Regulatory Approval is not required, then the first sale for end use or consumption of a
Licensed Product to a Third Party in the Territory in connection with the nationwide introduction of such Licensed Product in the Territory by Kinex, its Affiliates or sublicensees. 

1.28 “Generic Competition” shall be deemed to exist in the Territory as of any date if, during the two (2) immediately
preceding Calendar Years, (a) a Generic Product has a market share in the Territory of at least *** percent (***%) of the then combined unit volume of the competing Licensed 

  
 5 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
Product and the Generic Product, or (b) Net Sales by Kinex in the Territory decrease by at least *** percent (***%) with each of (a) and (b) measured as an average taken over such
two (2) Calendar Years as compared to the Calendar Year of Peak Sales. 
 1.29 “Generic Product” means any product
containing any Compound as an active pharmaceutical ingredient sold by a Third Party (excluding, for these purposes, an Affiliate or sublicensees of Kinex). 

1.30 “Hanmi Indemnified Parties” has the meaning set forth in Section 9.1. 

1.31 “Hanmi Intellectual Property” means the Hanmi Patent Rights, Hanmi Know-How and
Intellectual Property owned or Controlled by Hanmi or any of its Affiliates from the Orascovery Program. A list of the Hanmi Intellectual Property in the Territory as of the Effective Date is listed in Schedule 1.2. 

1.32 “Hanmi Know-Flow” means all Know-How that are owned or Controlled by Hanmi or any of its Affiliates. 

1.33 “Hanmi Patent Rights” means all Patent Rights that are owned or Controlled by Hanmi or any of its Affiliates. 

1.34 “IFRS” means International Financial Reporting Standards as adopted by the International Accounting Standard Board or
the Generally Accepted Accounting Principles as adopted in the United States (“GAAP”) will be consistently applied in each country based on the current accounting standards predominately utilized in such country. If a country does not
utilize either GAAP or the international accounting standards, the international accounting standards shall be applied in such country. 

1.35 “Improvements” means all inventions and Know-How, patentable or otherwise, made, created, developed, conceived or
reduced to practice by or on behalf of a Party and/or any of its Affiliates pursuant to activities relating to or contemplated by this Agreement during the Agreement Term, that 

  
 6 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
have application or relate to a Compound or a Licensed Product for use in the Field including developments in the manufacture, formulation, ingredients, preparation, presentation, means of
delivery or administration, dosage, indication, methods of use or packaging and/or sale of a Compound or a Licensed Product. 
 1.36
“IND” means an Investigational New Drug application obtained for purposes of conducting clinical trials in accordance with the requirements of the Act and the regulations promulgated thereunder, including all supplements and
amendments thereto relating to the use of a Compound or a Licensed Product in the Field. 
 1.37 “Initiation” means when an
IND is submitted for Clinical Studies to the Regulatory Authority of the Territory. 
 1.38 “Insurance” has the meaning set
forth in Section 9.6(a). 
 1.39 “Intellectual Property” means Patent Rights, Know-How, Copyrights, and Trademarks
collectively, including applications thereof, relating to the Compound(s) or Licensed Products, as well as any Improvements thereto. 
 1.40
“Kinex Indemnified Parties” has the meaning set forth in Section 9.1. 
 1.41 “Kinex Know-How” means
all Know-How that are owned or Controlled by Kinex as of the Effective Date and during the Agreement Term. 
 1.42 “Kinex Patent
Rights” means all Patent Rights that are owned or Controlled by Kinex as of the Effective Date and during the Agreement Term. 

1.43 “Kinex US License” means the license agreement executed on December 16, 2011 between Hanmi and Kinex US with
respect to the Orascovery Program. 

  
 7 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.44 “Know-How” means all proprietary information and technology, including
trade secret information, developments, discoveries, methods, techniques, formulations, Data, and other information, whether or not patentable, that relate to any Compound or any Licensed Product, or any improvement. 

1.45 “Law(s)” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect of
law of any governmental authority. 
 1.46 “Licensed Product(s)” means any and all pharmaceutical preparations in final
form (or, where the context so indicates, the form under development) containing any Compound as an active pharmaceutical ingredient for use in the Field in the Territory. 

1.47 “Liquidity Event(s)” means (i) a Public Offering, or (ii) the sale or other disposition of all or
substantially all of the assets of Kinex or Kinex US, or (iii) any consolidation or merger of Kinex or Kinex US with or into any other person, in such a way that under (i), (ii) or (iii) the holders of shares or other equity
securities of Kinex or Kinex US shall be entitled to receive cash or a class of equity securities that are publicly traded on a nationally recognized stock exchange in any jurisdiction or any combination thereof. 

1.48 “Losses” means any and all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues,
penalties (including penalties imposed by any governmental authority), costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including court costs, interest and reasonable fees of attorneys, accountants and other
experts) awarded or otherwise paid or payable to Third Parties. 
 1.49 “NDA” means a New Drug Application in the Territory
submitted to the SFDA to obtain approval for the marketing of a Licensed Product in the Territory, together with all subsequent submissions, supplements and amendments thereto. 

  
 8 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.50 “Net Profits” means revenues received by Kinex from any Sublicense or
from Direct Kinex Sales of a Licensed Product in the Territory subject to the following adjustments calculated on a consolidated basis with Kinex US in accordance with IFRS: 

With respect to revenues arising from each Sublicense and from Direct Kinex Sales, such revenues shall be reduced for (i) cost of goods,
(n) sales and marketing expenses for launch of a Licensed Product in the Territory, (iii) general and administrative costs (which shall not include depreciation and amortization attributable to the Licensed Product in the Territory)
related to the Commercialization of the Licensed Product for the Territory, and (iv) research and development costs incurred after initial Regulatory Approval in the Territory related to Clinical Studies necessary for market expansion. For the
avoidance of doubt, all costs and expenses as mentioned in (i), (ii), (iii), and (iv) herein shall not be deducted more than once from revenues arising from each Sublicense and from Direct Kinex Sales in the calculation of Net Profits. 

Where costs and expenses are shared among multiple Kinex products or projects or any combination of Sublicenses and Direct Kinex Sales in the
Territory, reasonable allocations based on such factors as the number of products, projects, Sublicenses or Direct Kinex Sales benefitting from the cost or expense and relative market share of each such product, project, Sublicense or Direct Kinex
Sales shall be utilized in the calculation of Net Profits. 
 Net Profits shall be calculated separately for each Licensed Product from and
after filing of the NDA for the applicable Licensed Product on a cumulative basis during the term of this Agreement for each Sublicense and all Direct Kinex Sales. To the extent aggregate, cumulative Net Profits for each Sublicense or for Direct
Kinex Sales is less than zero, the negative amount shall be carried forward and utilized in the calculation of Net Profits in the subsequent period until the negative balance is eliminated. 

  
 9 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.51 “Net Sales” means the gross sales amount of Licensed Products invoiced
to Third Parties by Kinex, its Affiliates and sublicensees, less the following deductions (to the extent included in such gross sales amount): 

(a) quantity and/or cash discounts therefor; 

(b) customs, duties, sales and similar taxes; 

(c) amounts allowed or credited by reason of rejections, return of goods (including as a result of recalls, market withdrawals and other
corrective actions), and retroactive price reductions or allowances specifically identifiable as relating to a Licensed Product including allowances and credits related to inventory management or similar agreements with wholesalers; 

(d) amounts incurred resulting from government (or any agency thereof) mandated rebate programs in the Territory; 

(e) Third Party rebates, patient discount programs, administrative fees and chargebacks or similar price concessions related to the sale of a
Licensed Product, to the extent permitted by applicable law; 
 (f) bad debt recognized for accounting purposes as not collectible; 

(g) the expenses for insurance, freight, packing, shipping and transportation; 

(h) commissions paid to agents or distributors to secure tender offers or other purchases by local authorities; and 

(i) as agreed by the Parties, such agreement not to be unreasonably withheld, any other specifically identifiable amounts included in a
Licensed Product’s gross sales amount that were or ultimately will be credited and that are similar to those listed above, all in accordance with IFRS. 

  
 10 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 All such discounts, allowances, credits, rebates and other deductions shall be fairly and
equitably allocated to a Licensed Product, and, to the extent applicable, other products or services of Kinex or its Affiliates or sublicensees such that the Licensed Products do not bear a disproportionate portion of such deductions. For the
avoidance of doubt, Net Sales shall not include sales by Kinex to its Affiliates or sublicensees for resale; provided that, if Kinex sells Licensed Products to an Affiliate or sublicensee for resale, then the Net Sales calculation
shall include the amounts invoiced by such Affiliate or sublicensee to Third Parties on the resale of such Licensed Products. For purposes of this Agreement, “sale” shall not include transfers or other distributions or dispositions of
Licensed Products, at no charge, for regulatory purposes, clinical trials, samples, free products or in connection with patient assistance programs or other charitable purposes or to physicians or hospitals for promotional purposes. Licensed
Products shall be considered “sold” only when billed or invoiced. 
 1.52 “Ongoing Clinical Study” means Clinical
Studies with enrolled patients that are in the process of being conducted. For the avoidance of doubt, this does not include Clinical Studies where no patient dosing has occurred regardless of enrollment of patients. 

1.53 “Orascovery Program” means the Hanmi program dedicated to the research, discovery and development of compounds that
enhance or increase the oral absorption of pharmaceutical preparations in humans or animals. 
 1.54 “Oratecan” means any
oral dosage, chemotherapy drug that contain the Compound and Irinotecan as active pharmaceutical ingredients. 
 1.55
“Oraxol” means any oral dosage, chemotherapy drug that contain the Compound and Paclitaxel as active pharmaceutical ingredients 

1.56 “Party” means Hanmi or Kinex, as the context may require. 

1.57 “Parties’ Patent Rights” has the meaning set forth in Section 6.3(a). 

  
 11 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.58 “Patent Rights” means any patents, patent applications, certificates of
invention, or applications for certificates of invention and any supplemental protection certificates, together with any extensions, registrations, confirmations, reissues, substitutions, divisions, continuations or
continuations-in-part, reexaminations or renewals thereof that relate to any Compound, any Licensed Product or any Improvement, including methods of development, manufacture, formulation, preparation,
presentation, means of delivery or administration, dosage, packaging, sale or use relating to the Compound, Licensed Product or Improvement. 

1.59 “Peak Sales” means the highest Net Sales of the applicable Licensed Product achieved during any Calendar Year following
the First Commercial Sale of such Licensed Product within the Territory. 
 1.60 “Phase I Clinical Study(ies)” means the
initial introduction of an investigational new drug into humans primarily designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early
evidence on effectiveness, and may also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological
phenomena or disease processes. 
 1.61 “Phase II Clinical Study(ies)” means the Clinical Study related to the product, in
particular, the study that will show the efficacy of the product and also provide guidance to the effective dose regimen required. In general, this type of study will determine the effective dose regimen for the clinical indication. Safety data is
also collected in this type of study. 
 1.62 “Phase III Clinical Study(ies)” means the Clinical Study related to the
product, in particular, the study that is a registration study designed to demonstrate statistically (p-value of less than 0.05 or <0.025 for split-alpha study design) the efficacy of the drug for specific indications. This type of study is
usually conducted after agreement with the Regulatory Authority that a positive result from such a study conducted under good clinical practice will be enough for the Regulatory Authority to provide marketing approval of the product. 

  
 12 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.63 “Prime Rate” means the rate announced from time to time by HSBC Bank,
N.A. as its “prime rate” in New York, New York, USA which is the base rate upon which other rates charged at such bank are based, and is the best rate available to premium customers at such bank. 

1.64 “Product Label(ing)” shall have the same meaning as defined in the Act and as interpreted by the Regulatory Authority in
the Territory. 
 1.65 “Proprietary Information” means any and all scientific, clinical, technological, regulatory,
marketing, financial and commercial information or data, whether communicated in writing, orally or by any other means, which is owned and under the protection of one Party and is provided by that Party to the other Party in connection with this
Agreement, and shall include Hanmi Know-How and Kinex Know-How, as applicable. 
 1.66 “Public Offering” means the
consummation of an underwritten public offering by Kinex or Kinex US for any class of its equity securities. 
 1.67 “Regulatory
Approval” means approval by the relevant Regulatory Authority of an NDA or other Drug Approval Application, health registration, common technical document, regulatory submission, notice of compliance and any other license or permit required
to be approved for the supply, manufacture, use, storage, distribution, import, export, transport, promotion, marketing and sale of a Licensed Product in a country, region or other regulatory jurisdiction. 

1.68 “Regulatory Authority” means any governmental authority in a country, region or other regulatory jurisdiction that
regulates the supply, manufacture, use, storage, distribution, import, export, transport, promotion, marketing and sale of a Licensed Product. 

  
 13 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 1.69 “Sublicense” means any license of some or all of Kinex’s rights
under this Agreement to a Third Party. 
 1.70 “SFDA” means the Regulatory Authority in Mainland China. 

1.71 “Substantial Level Generic Competition” shall be deemed to exist in the Territory as of any date if, during the two
(2) immediately preceding Calendar Years, (a) a Generic Product has a market share in the Territory of at least *** percent (***%) of the then combined unit volume of the competing Licensed Product and the Generic Product, or (b) Net
Sales by Kinex in the Territory decrease by at least *** percent (***%) with each of (a) and (b) measured as an average taken over such two (2) Calendar Years as compared to the Calendar Year of Peak Sales. 

1.72 “Territory” means Mainland China. 

1.73 “Third Party(ies)” means a person or entity who or which is neither a Party nor an Affiliate of a Party. 

1.74 “Trademark” means all trademark(s) for which either Party has sought registration and all related service marks, domain
names and other trademark related rights relating to the Licensed Products. 
 1.75 “Valid Claim” means any claim in an
active patent application or issued in an unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction following exhaustion of all possible appeal
processes, and which has not been admitted to be invalid or unenforceable through reissue, reexamination or disclaimer and has not been terminated for failure to pay maintenance fees. 

  
 14 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 ARTICLE 2 

GRANT OF RIGHTS 
 2.1 Grants by
Hanmi. Subject to the terms and conditions of this Agreement, Hanmi hereby grants to Kinex an exclusive right and license throughout the Territory as defined (including the right to grant Sublicenses to Third Parties with prior written notice to
Hanmi) to practice under the Hanmi Intellectual Property in order to develop, label, package, import, export, promote, distribute, make, use, sell, offer for sale, register, commercialize and otherwise exploit the Compounds and Licensed Products
containing the Compounds in the Field and a non-exclusive right to manufacture the Compounds and Licensed Products outside the Territory but solely for sales within the Territory; provided, however, that, notwithstanding the exclusive rights
granted to Kinex hereunder, Hanmi shall retain the right to use the Hanmi Intellectual Property in the Territory solely as necessary to perform its obligations under this Agreement. With respect to sales to Third Party distributors or other parties
purchasing Licensed Products for resale, Kinex shall use reasonable efforts to restrict such resales to within the Territory. 
 2.2 Retained Rights; No
Implied Licenses. All rights not specifically granted to Kinex under this Agreement are reserved and retained by Hanmi. Nothing in this Agreement shall be deemed to constitute the grant of any license or other right to Kinex, to or in respect of
any product, patent, trademark, Proprietary Information, trade secret or other data or any other intellectual property of the other Party, except as set forth under this Agreement. Hanmi retains the right to manufacture Compounds or Licensed
Products within the Territory for sales outside the Territory. For the avoidance of doubt, Hanmi shall not market, distribute, sell and import the Licensed Products within the Territory. 

2.3 First Right of Negotiation. Kinex hereby grants to Hanmi a one time, right of first negotiation to purchase all of Kinex’s rights in Oraxol
under this Agreement and a one time, right of first negotiation to purchase all of Kinex’s rights in Oratecan under this Agreement. Such rights must be exercised with respect to Oraxol or Oratecan during Development of the applicable product
and prior to (i) First Commercial Sale of the applicable product or (ii) receipt by Hanmi of written notice from Kinex of the 

  
 15 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
Sublicense of the applicable product to a Third Party under Section 2.1. The purchase price for such rights in Oraxol or Oratecan shall be determined by an internationally recognized
investment banking firm with an office in Hong Kong selected by mutual agreement of the Parties. 
 With respect to the right of first
negotiation, Hanmi shall send written notice of its intent to purchase all rights under this Agreement in Oraxol or Oratecan to Kinex together with a list of at least five internationally recognized investment banking firms acceptable to Hanmi
(“Notice of Intent”). Kinex shall have thirty (30) days from the date of the Notice of Intent to agree to one of the investment banking firms proposed by Hanmi. If Kinex disagreed with all the investment banking firms proposed by
Hanmi, Hanmi shall have fourteen (14) days to provide another list of five (5) such firms, and Kinex shall have fourteen (14) days after receipt of the second list to agree to one of the investment banking firms proposed by Hanmi on
the first or second list. This process can repeat for a third cycle, but during the third cycle, Kinex must agree to one of the investment banking firms on the first, second or third list. The investment banking firm shall be retained to value
Kinex’s rights in the applicable product under this Agreement. After receipt of the valuation of the investment banking firm, the Kinex and Hanmi shall negotiate in good faith for an additional thirty (30) days thereafter in an effort to
execute a definitive purchase or sublicense agreement. If the parties fail to enter into a definitive purchase or sublicense agreement within sixty (60) days of the date of the valuation of the investment banking firm, then Kinex shall be free
to sublicense the applicable product or Develop and Commercialize the product for its own account under this Agreement and Hanmi’s right under this Section 2.3 with respect to such product shall expire and be of no further force or effect;
provided, however, in the event Hanmi wishes to continue discussions on the definitive purchase or sublicense agreement after such sixty (60) day period expires, Kinex’s right to Sublicense, Develop and Commercialize the product for
its own account and the expiration of Hanmi’s right under this Section 2.3 may be suspended(upon prior written consent from Kinex) for an additional sixty (60) days during which time the Parties shall continue to discuss a definitive
purchase or sublicense agreement in good faith. Hanmi shall be responsible to pay all expenses and fees of the investment banking firm. 

  
 16 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 ARTICLE 3 

INFORMATION TRANSFER; DEVELOPMENT AND COMMERCIALIZATION; 

REGULATORY MATTERS 
 3.1 Information
and Transfer of Hanmi Intellectual Property. As soon as practicable, but in no event later than thirty (30) days after the Effective Date, Hanmi shall disclose and deliver to Kinex electronic copies in the English language (or, upon
Kinex’s request, copy of the originals) of all Data necessary for continued Development and Commercialization in the Territory including, but not limited to, English translations of (i) the IND submitted in Korea, (ii) the Phase I
Clinical Study report and Phase II Clinical Study report completed in Korea for HM30181A (a P-Glycoprotein inhibitor), and (iii) any other research report. In addition to the foregoing, Hanmi shall provide Kinex with such assistance as Kinex
may reasonably request (at Kinex’s cost and expenses) in connection with the foregoing disclosures, including making available at their place of employment (or such other location as the Parties may mutually agree upon) the assistance of such
persons that were involved with the Orascovery Program, Clinical Studies and the Hanmi Intellectual Property. The Party requesting copies of Data shall reimburse the other Party for the cost of providing copies of such Data. 

3.2 Ongoing Disclosure. At least twice in each Calendar Year, each Party shall disclose and deliver to the other Party electronic copies in the English
language (or, upon request of a Party with the need, copies of the originals) all discoveries and developments within its Orascovery Program including all new Compounds, new Data, and the Hanmi Intellectual Property as necessary for continued
Development and Commercialization in the Territory. 
 3.3 Development and Commercialization. 

(a) General. Kinex shall be responsible for and shall itself, or through its Affiliates or sublicensees, conduct Development and
Commercialization in the Territory before and during the Agreement Term as described by this Agreement. Within ninety (90) days after the Effective Date, Kinex 

  
 17 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
shall prepare a draft Development plan, in English, consistent with regional development requirements. A budget, in English related to the Development and Commercialization for the Territory will
also be submitted to the Development and Commercialization Steering Committee (as defined in Section 3.5) which will agree on and oversee the plan for Development and Commercialization during the Agreement Term. If 

(i) Kinex fails to file an IND for Oraxol with the Regulatory Authority in the Territory within six (6) months after the
latest of (w) completion of all Chinese translations necessary for the filing of an IND with the Regulatory Authority in the Territory, (x) completion of all manufacturing and toxicology studies necessary for the filing of an IND with the
Regulatory Authority in the Territory, (y) the date Hanmi and Kinex agree that all studies necessary for the filing of an IND with the Regulatory Authority in the Territory have been completed, or (z) the date of the final study report for
the last of any additional studies that are necessary for the filing of an IND with the Regulatory Authority in the Territory, or 

(ii) Kinex fails to commence Clinical Studies for Oraxol within twelve (12) months after the date of approval of an IND by
the Regulatory Authority in the Territory, 
 then, with both (i) and (ii) above being subject to an extension on the foregoing timelines of up to
twelve (12) months at the reasonable request of Kinex, Hanmi shall have the option, if it elects to do so, to terminate all rights and licenses under this Agreement upon the end of the applicable period as such period may be extended in
accordance with the above. 
 (b) Summary Reports. Upon Hanmi’s sixty (60) day prior written request, made within thirty
(30) days after the end of the first Calendar Year following the Effective Date and each year thereafter during the Agreement Term, if timely requested, Kinex shall provide Hanmi with a written summary of Development and Commercialization
undertaken in the Territory during the then current Calendar Year consistent with written reports issued by Kinex in the ordinary course of its business. 

  
 18 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (c) Clinical Studies. Kinex will, either directly or through its Affiliates or
sublicensees conduct and administer all the Clinical Studies in the Territory for Licensed Products as identified and agreed upon in the Development plan or as approved from time to time by the Development and Commercialization Steering Committee.

 (d) Referencing Data. The Data and results of any Clinical Studies or other studies conducted by a Party or its ex-Territory
partners shall be made available to the other Party for referencing at no cost to the requesting Party for regulatory filing purposes, and each party hereby grants to the other Party a right of reference to use such Data for the Development and
Commercialization of the Compounds and Licensed Products, provided, however, that with respect to the right granted to Kinex, such right shall be limited to the Development and Commercialization of the Compounds and the Licensed Products in
the Field in the Territory. 
 (e) Payment of Development and Commercialization Costs. Kinex shall be responsible for all reasonable
costs associated with Development and Commercialization in the Territory. Notwithstanding the generality of the foregoing, Kinex shall reimburse Hanmi for the direct and actual costs incurred by Hanmi in carrying out any Development within the
Territory that was authorized or approved in writing in advance by Kinex, subject to a full accounting of such direct costs. 
 (f)
Records. Under this Agreement, Kinex shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in accordance with good industry practice, which shall be complete and accurate
in all material respects and shall fully and properly reflect all work done and results achieved, including all Know-How and including individual case report forms, in the form required by applicable Laws. Hanmi shall have the right, upon at least
sixty (60) days prior written notice to Kinex and no more than once in any Calendar Year, to inspect and audit such records. Hanmi shall reimburse Kinex for any costs incurred by Kinex with respect to any such inspection and audit by Hanmi.

  
 19 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (g) Promotional Materials and Activities. Kinex shall create and develop the
advertising and promotional materials for the Licensed Products in the Territory with the written approval of Hanmi(which shall not be unreasonably withheld) with respect to all such materials. As holder of the Regulatory Approvals in the Territory,
Kinex shall be responsible for all submissions and interactions with the Regulatory Authorities regarding approval of all Licensed Product-related promotional materials that require Regulatory Approval. 

(h) Ownership of Copyrights and Trademarks. The parties shall cooperate with respect to the establishment of all Trademarks and
Copyrights for each Licensed Product in the Territory. Hanmi retains all rights to establish a global brand for each Licensed Product and shall own all Copyrights and Trademarks for each Licensed Product in the Territory with respect to such global
branding strategy. Kinex shall have the right, with good cause and after consultation with Hanmi, to establish a brand for a Licensed Product in the Territory that is distinct from Hanmi’s global branding, and Kinex shall own all such distinct
Copyrights and Trademarks. Each Party shall be responsible for searching, clearing and filing applications for registration of its own Copyrights, Trademarks and trade dress at its own cost and responsibility. Hanmi shall execute all documents and
take all actions as are requested by Kinex with respect to such filings and registrations. Hanmi shall have the right to use the Kinex Trademarks and Copyrights with respect to the Compounds and Licensed Products upon Kinex’s prior written
consent. 
 (i) Sales of Licensed Products. All sales of Licensed Products shall be made, recorded, invoiced and collected by Kinex
or its Affiliates or sublicensees. All terms regarding Licensed Product sales, including terms with respect to credit, pricing, cash discounts, rebates, chargebacks, bad debt write-offs, and other fees and
charges, and returns and allowances shall be set solely by Kinex in accordance with reasonable industry standards. 
 (j) Supply of
Licensed Product. During the Agreement Term, Hanmi shall use its best efforts to assist Kinex to procure, in accordance with regulatory requirements and as requested by Kinex, the requirements for Licensed Products for Clinical Studies and
Regulatory Approval in the Territory. If 

  
 20 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
Hanmi is directly manufacturing the Licensed Product for its own purposes, it shall supply the Licensed Product to Kinex at a purchase price payable by Kinex equal to Hanmi’s cost for
manufacturing the Licensed Products. For the avoidance of doubt, Kinex shall be responsible for any customs duties. If Kinex elects to directly manufacture its own investigational products containing any Compound, Hanmi shall have the right to
purchase such investigational products from Kinex for Clinical Studies and Regulatory Approval outside the Territory at a purchase price payable by Hanmi equal to Kinex’s cost for manufacturing the investigational products. 

3.4 Regulatory Matters. 
 (a)
Responsibility of Kinex. 
 From and after the Effective Date: 

(i) Kinex shall have sole authority and responsibility for the timely preparation, filing and prosecution of all filings,
submissions, authorizations or approvals with Regulatory Authorities, and shall own and control all such filings, submissions, authorizations and approvals, including any IND, NDA or other Drug Approval Application in the Territory in accordance
with reasonable industry standards. Kinex shall provide copies of all such filings, submissions, authorizations and approvals upon reasonable request from Hanmi, at Hanmi’s sole cost and expense. 

(ii) Kinex shall be the primary contact with each Regulatory Authority in the Territory and shall be solely responsible for all
communications with each Regulatory Authority that relate to any IND, NDA, or other Drug Approval Application in the Territory, provided, however, that upon the reasonable request of Kinex, Hanmi shall provide appropriate personnel to
participate in discussions with a Regulatory Authority regarding the regulatory review process and shall assist and consult with Kinex in applying for Regulatory Approval at Kinex’s cost and expense. 

(iii) From and after receipt of each Regulatory Approval, Kinex shall have exclusive authority and responsibility to submit all
reports or amendments necessary to maintain Regulatory Approvals and to seek revisions of the conditions of each such Regulatory Approval in the Territory and shall keep Hanmi informed of any such actions. Kinex shall have sole authority and
responsibility to seek and/or obtain any necessary approvals for any Product Label, or prescribing information, package inserts, monographs and packaging used in connection with a Licensed Product, in addition to promotional materials used in
connection with a Licensed Product in the Territory. Kinex shall determine whether the foregoing items require Regulatory Approval in the Territory. 

  
 21 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) Responsibility of Hanmi 

(i) Hanmi shall fully cooperate and assist Kinex, upon Kinex’s request, with respect to Kinex’s performance of its
obligations under this Agreement. Hanmi shall not he required, however, to incur any Third Party costs to meet its obligation to cooperate and assist Kinex under this Section. If Hanmi’s cooperation and assistance will be limited due to
Third Party costs, Hanmi shall provide Kinex an estimate, including supporting documentation, of such Third Party costs. Unless otherwise agreed herein, or with the prior agreement of Kinex otherwise, Kinex shall not be responsible for any payment
to Hanmi in consideration of any cooperation or assistance rendered by Hanmi. 
 (ii) Regulatory Cooperation. Each
Party is responsible for matters concerning adverse drug reactions, safety information and compliance with regulatory requirements. Each Party shall, upon the request of the other Party, provide any such data in each Party’s actual possession
to the other Party that is required by the Chinese Regulatory Authority. The Parties hereby agree that they will each make their best Commercially Reasonable Efforts in coordinating their respective regulatory, Development and Commercialization
efforts under this Agreement. 

  
 22 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 3.5 Appointment and Administration of Development and Commercialization Steering Committee for the Territory

 (a) Oversight and review of the Development and Commercialization of the Licensed Products under this Agreement shall be managed by the
same four (4) person steering committee established under the Kinex US License unless otherwise mutually agreed by the Parties. If a separate steering committee is established under this Agreement, the Development and Commercialization of the
Licensed Products under this Agreement shall be managed by a four (4) person steering committee which will include two (2) representatives of each of Kinex and Hanmi (the “Development and Commercialization Steering
Committee”) and will be chaired by one of the representatives of Kinex. All actions, decisions and approvals of the Development and Commercialization Steering Committee shall be determined upon an affirmative majority vote of its members.
If there is a tie vote (after the process described in Article 3.5(c)), Kinex CEO will have the casting vote. 
 (b) One
(1) member appointed by each Party will be a senior officer of such Party who is either (i) responsible for product development or (ii) has substantial experience in product development for similar products who is acceptable to the
other Party. Each Party, at its sole discretion, may at any time during the Agreement Term replace either of its appointed members with prior written notice to the other Party. Each Party will use commercially reasonable efforts to cause its
respective representatives to attend all meetings of the Development and Commercialization Steering Committee. Each Party will bear its respective travel and out-of-pocket expenses incurred by its members or representatives in connection with the
Development and Commercialization Steering Committee’s meetings. 
 The Development and Commercialization Steering Committee will meet
at least once every Calendar Quarter or more or less frequently as the Parties mutually deem appropriate, at a time and place agreed by the Parties. The Development and Commercialization Steering Committee may also convene, vote or hold discussions
from time to time through other methods of communication, as deemed necessary or appropriate by the Parties, including without limitation, telephone, video conference or email. 

  
 23 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (c) In the event there is a disagreement among the members of the Development and
Commercialization Steering Committee, the members of the Development and Commercialization Steering Committee shall promptly present such issue in dispute to the relevant executive at Kinex and Hanmi who has the principal responsibility for the work
under this Agreement. Once informed, the executives shall meet to discuss each party’s view and to clarify the basis for such disagreement. If such executives are unable to resolve such dispute within thirty (30) days of such meeting,
(i) such dispute shall be submitted to a panel of three independent experts agreed upon by Hanmi and Kinex if it is a clinical dispute, (ii) such dispute (if other than clinical) shall be submitted to arbitration if it is within the
framework of this Agreement, or (iii) Kinex’s decision shall be final and binding if such dispute is not clinical or within the framework of this Agreement and is applicable to issues only within the Territory. The arbitration shall be
conducted in Singapore in accordance with the Singapore International Arbitration Centre Rules. If a disagreement or dispute under this Section results in a delay in Kinex’s ability to meet any timeline provided for in this Agreement, such
timeline shall be extended for a period of time equal to the length of such delay. 
 (d) The Development Steering and Commercialization
Committee shall be responsible for (i) approval and amendment, from time to time, of the plan for Development and Commercialization, (ii) the protocols for Clinical Trials of any Licensed Product, (iii) approval of all contracts
relating to the Development of any Licensed Product, (iv) the formulation used in respect of any Licensed Product, and (v) contracts relating to the Commercialization of any Licensed Product. 

  
 24 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 ARTICLE 4 

PAYMENTS AND STATEMENTS 
 4.1 Upfront
Fee. Upon execution of this Agreement, Kinex or its Affiliates shall pay to Hanmi US$100,000. Kinex or its Affiliates shall remit all applicable withholding taxes in or outside of the Territory required to be paid on behalf of Hanmi with respect
to such payment and remit the net amount to Hanmi. The Parties shall cooperated and provide each other with all information and documentation required to take advantage of any applicable tax treaties to reduce the tax burden of each Party. 

4.2 Royalties. 
 (a) During each Calendar
Quarter during the Agreement Term, Kinex shall calculate Hanmi’s aggregate interest in Net Profits under this Agreement based on its separate interest in the Net Profits from each Sublicense and from Direct Kinex Sales based upon the following
tiered rates (“Net Profits Interest(s)”): 
 With respect to Oraxol, Hanmi shall have the following Net Profits Interests:

 (i) For each Sublicense entered into prior to an IND submission for Oraxol to the SFDA
                     ***% 

(ii) For each Sublicense entered into after submission of an IND for Oraxol to the SFDA but prior to Completion of a Phase I
Clinical Study                      ***% 

(iii) For each Sublicense entered into after Completion of a Phase I Clinical Study but prior to Completion of a Phase III
Clinical Study                      ***% 

(iv) For each Sublicense entered into after Completion of a Phase III Clinical Study but prior to SFDA Regulatory Approval
                     ***% 

(v) For each Sublicense entered into after SFDA Regulatory Approval and with respect to all Direct Kinex Sales
                     ***% 

  
 25 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 With respect to Oratecan, Hanmi shall have the following Net Profits Interests (which is
the same as for Oraxol): 
 (vi) For each Sublicense entered into prior to an IND submission for Oratecan to the SFDA
                     ***% 

(vii) For each Sublicense entered into after submission of an IND for Oratecan to the SFDA but prior to Completion of a Phase I
Clinical Study                      ***% 

(viii) For each Sublicense entered into after Completion of a Phase I Clinical Study but prior to Completion of a Phase III
Clinical Study                      ***% 

(ix) For each Sublicense entered into after Completion of a Phase Ill Clinical Study but prior to SFDA Regulatory Approval
                     ***% 

(x) For each Sublicense entered into after SFDA Regulatory Approval and with respect to all Direct Kinex Sales
                     ***% 
 With
respect to each Licensed Product other than Oraxol and Oratecan, Hanmi shall have the following Net Profits Interests 
  

	 	(i)	For each Sublicense entered into prior to the date of the final toxicology report necessary for submission of an IND to SFDA
                     ***% 

  

	 	(ii)	For each Sublicense entered into after the date of the final toxicology report necessary for submission of an IND to SFDA but prior to Completion of Phase I Clinical Study
                     ***% 

  

	 	(iii)	For each Sublicense entered into after Completion of a Phase I Clinical Study but prior NDA submission
                     ***% 

  

	 	(iv)	For each Sublicense entered into after NDA submission and with respect to all Direct Kinex Sales
                     ***% 

  
 26 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) For each Calendar Quarter during the Agreement Term, Kinex shall, pursuant to
Section 4.3(a) pay to Hanmi a royalty equal to the sum of (i) Net Profits for each Sublicense and Net Profits from Direct Kinex Sales (including negative numbers) calculated in the current Calendar Quarter and multiplied by the applicable
Net Profits Interest for each such Sublicense or Direct Kinex Sales minus (ii) all payments previously made to Hanmi in all preceding Calendar Quarters (“Royalties”). 

(c) The Net Profits Interests set forth in 4.2(a)shall be (i) reduced by *** percent (***%) for a Licensed Product in the Territory in
which Generic Competition exists and (ii) terminated for a Licensed Product in the Territory in which Substantial Generic Competition exists; provided, however, that if Substantial Level Generic Competition exists in the Territory for
all Licensed Products, then the Agreement Term shall terminate with respect to the Territory, and no further Royalties shall be payable by Kinex to Hanmi in the Territory. 

4.3 Royalty Reports and Payments. 
 (a)
Royalty Payments. Within seventy five (75) days following the end of each Calendar Quarter during the Agreement Term, Kinex shall submit to Hanmi an accounting report for such applicable Calendar Quarter within the Territory, which sets
forth the Net Profits by Sublicense and Direct Kinex Sales, Royalties previously paid, and current Royalties payable by Kinex to Hanmi for such Calendar Quarter, with a breakdown of all revenues and expenses in any such calculations, in accordance
with the definition of “Net Profits”. Any conversion to Dollars shall be calculated in accordance with Section 4.4(c). In the event of any royalty reduction during any Calendar Quarter due to Generic Competition in the Territory, the
report for such Calendar Quarter shall also provide the basis for the 

  
 27 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
determination of such Generic Competition. Royalties shown to have accrued by each report shall be due and payable on the date such report is due. If the Net Profits used in the calculation of
Royalties in any Calendar Quarter is subsequently adjusted, the adjustment shall be utilized in all subsequent calculations of Net Profits. 

(b) Reports. Kinex shall also furnish Hanmi a written report for each Licensed Product in the Territory during the first four
(4) Calendar Quarters commencing after the termination of the royalty obligations for such Licensed Product in the Territory stating the basis for Net Sales then being free of royalty obligations hereunder. Kinex shall thereafter have no
further obligation to include in any written reports the Net Sales of such Licensed Product in such Territory for purposes of the royalty calculation for any Calendar Quarter. This obligation shall survive the termination or expiration of this
Agreement in the Territory. 
 (c) Records. Each Party shall keep and require its Affiliates and sublicensees to keep complete and
accurate records in sufficient detail to permit accurate determination of all amounts necessary for calculation and verification of all payment obligations set forth in this Article 4 for a period of thirty six (36) months from the end of
the relevant Calendar Quarter. 
 4.4 General Payment Provisions. 

(a) Payment Method. All payments under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to
an account designated by Hanmi. 
 (b) Withholding Taxes. Kinex may deduct the amount of any taxes imposed on Hanmi which are
required to be withheld or collected by Kinex, its Affiliates or sublicensees under the laws, rules or regulations of any country on amounts owing from Kinex to Hanmi hereunder. Any such taxes required to be withheld or collected shall be an expense
of Hanmi. To the extent Kinex, its Affiliates or sublicensees pay such withholding taxes to the appropriate governmental authority on behalf of Hanmi; Kinex shall promptly deliver to Hanmi proof of payment of such taxes. 

  
 28 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (c) Currency Exchange. For purposes of computing Royalties in the Territory, the Net
Sales shall be converted to Dollars using the year-to-date average rate of exchange for Dollars used by Kinex for its internal financial accounting purposes; provided, however, that if for any reason conversion into Dollars cannot be made in
the Territory, then notwithstanding the provisions of Section 4.4(a), payment may be made in the currency of the Territory by deposit in the name of Hanmi in a bank account designated by it in the Territory. 

(d) Financial Accounting Standards. Except as otherwise defined herein, all financial calculations by either Party under this Agreement
shall be calculated in accordance with IFRS. In addition, all calculations shall give pro rata effect to and shall proportionally adjust (by giving effect to the number of applicable days in such Calendar Quarter) (i) for any Calendar
Quarter that is shorter than a standard Calendar Quarter or any Calendar Year that is shorter than four (4) consecutive full Calendar Quarters, or (ii) as a result of a determination, in accordance with the terms of this Agreement, that
the first or last day of such Calendar Quarter (including as a result of termination of this Agreement) shall be deemed other than the actual first or last day of such Calendar Quarter, or that the first or last day of such Calendar Year shall be
deemed other than the actual first or last day of such Calendar Year. 
 4.5 Audits. Upon the written request of Hanmi, Kinex shall permit an
independent certified public accounting firm of recognized standing, selected by Hanmi and acceptable by Kinex (provided that such accounting firm shall not be retained or compensated on a contingency basis and shall have entered into a
confidentiality agreement with Hanmi in the form and substance reasonably satisfactory to Kinex), to have access not more than once in any Calendar Year, during normal business hours, to such of the records of Kinex as may be reasonably necessary to
verify the accuracy of the reports under Section 4.3 hereof for any year ending not more than twenty four (24) months prior to the date of such request. The accounting firm shall disclose to Hanmi whether the reports are correct or
incorrect, the specific details concerning any discrepancies (including the accuracy of the calculation of Net Profits and the resulting effect of such calculations on the amounts payable by Kinex under this Agreement) and such other information
that should properly be contained in a report required under this Agreement (the “Audit Report”). 

  
 29 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (a) If such accounting firm concludes that additional amounts were owed during such year, and
Kinex agrees with such conclusion, then Kinex shall pay the additional payments, together with interest at the Prime Rate on the amount of such additional payments, within thirty (30) days of the date Hanmi delivers the Audit Report to Kinex.
In the event that Kinex disagrees with the accounting firm’s conclusion, Kinex shall not have the obligation to make any additional payments to Hanmi until there is a mutual agreement of the Parties regarding the amount owed by Kinex. For the
avoidance of doubt, Kinex is not obligated to pay any interest for the period during which the Parties were in dispute of the accounting firm’s conclusion and amount owed thereunder. In the event such accounting firm concludes that amounts were
overpaid by Kinex during such period, Hanmi shall repay Kinex the amount of such overpayment, together with interest at the Prime Rate on the amount of such overpayment, within thirty (30) days of the date the auditing Party delivers to the
audited Party such accounting firm’s Audit Report. The fees charged by such accounting firm shall be paid by Hanmi, provided, however, that if an error in favor of the Hanmi of more than five percent (5%) of the payments due
hereunder for the period being reviewed is discovered, then the fees and expenses of the accounting firm shall be paid by Kinex. 
 (b) Upon
the expiration of twenty four (24) months following the end of any year for which Kinex or Hanmi has made payment in full of amounts payable with respect to such year, and in the absence of negligence or willful misconduct of Kinex or Hanmi or
a contrary finding by an accounting firm pursuant to Section 4.5(a), such calculation shall be binding and conclusive upon Kinex or Hanmi, and Kinex or Hanmi, as applicable, shall be released from any liability or accountability with respect to
royalties or other payments for such year. 
 4.6 Right to Replace Payment Structure. Notwithstanding anything in this Agreement to the contrary,
Kinex agrees that Hanmi shall have a one-time option to replace the payment structure of this Agreement with the payment structure more fully described in Schedule 1.3. In the event Hanmi should so elect, the Parties agree to execute the
amendment agreement attached hereto as Schedule 1.3, which provides that only the payment structure in this Article 4 shall be replaced and all other terms and conditions of this Agreement shall remain in full force and effect against the
Parties. Hanmi shall deliver written notice of such election to Kinex, and such election shall be effective as of January 1 of the Calendar Year beginning immediately following the date of receipt of such notice by Kinex. 

  
 30 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 ARTICLE 5 

REPRESENTATIONS AND WARRANTIES 
 5.1
General Representations. Each Party hereby represents and warrants to the other Party as follows: 
 (a) Such Party is a corporation
duly organized, validly existing and is in good standing under the laws of the jurisdiction of its incorporation or formation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of
its business or the ownership of its properties requires such qualification and failure to have such would prevent it from performing its obligations under this Agreement; 

(b) The execution, delivery and performance of this Agreement by such Party has been duly authorized by all necessary corporate action and do
not and will not (i) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or any provision of its charter or bylaws; or
(ii) conflict with or constitute a default under any other agreement to which such Party is a party; 
 (c) This Agreement has been
duly executed and is a legal, valid and binding obligation of such Party, enforceable against it in accordance with the terms and conditions hereof, except as enforceability may be limited by (i) any applicable bankruptcy, insolvency,
reorganization, moratorium or similar law affecting creditor’s rights generally, or (ii) general principles of equity, whether considered in a proceeding in equity or at law; 

  
 31 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (d) Such Party is not under any obligation to any person or entity, contractual or otherwise,
that is in conflict with the terms of this Agreement, nor shall such Party undertake any such obligation during the Agreement Term; 
 (e)
Such Party has obtained all authorizations, licenses, permits, consents and approvals, governmental or otherwise, necessary for the execution and delivery of this Agreement, and to otherwise perform such Party’s obligations under this
Agreement; 
 (f) Neither Party, nor any of its Affiliates, are a party to, or are otherwise bound by, any oral or written agreement that
will result in any person or entity obtaining any interest in, or that would give to any Third Party any right to assert any claim in or with respect to, any of such Party’s or the other Party’s rights under this Agreement; and 

(g) Such Party shall perform its obligations hereunder in accordance with all applicable Laws. 

5.2 Additional Representations and Warranties of Hanmi. Hanmi represents and warrants to Kinex that: 

(a) As of the Effective Date in the Territory, (i) to Hanmi’s best knowledge, there is no Third Party infringement of any of the
Hanmi Intellectual Property; (ii) the Hanmi Intellectual Property is in full force and effect where filed; (iii) the Hanmi Patent Rights where filed are not subject to any pending or threatened re-examination, re-issue, opposition,
interference, challenge, litigation proceeding or other claim; and (iv) if Hanmi has not filed or prosecuted any patent applications with respect to the Hanmi Intellectual Property, Hanmi shall cause and ensure that Kinex is granted Data
exclusivity under this Agreement in the Territory and shall perform all necessary requirements in connection therewith. 

  
 32 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) Hanmi has not committed any act, or omitted to commit any act, that may cause the Hanmi
Patent Rights where filed to expire prematurely or be declared invalid or unenforceable, or that stops Hanmi from enforcing the Hanmi Patent Rights where filed against any Third Party; 

(c) As of the Effective Date in the Territory, (i) Hanmi has the sole right to use, disclose and enable Kinex to use and disclose (in
each case under appropriate conditions of confidentiality) the Hanmi Know-How; and (ii) the Hanmi Intellectual Property is not subject to any encumbrance, lien, license or claim of ownership by any Third Party; 

(d) At no time during the Agreement Term shall Hanmi assign, transfer, encumber, dispose of, or grant rights in, or with respect to, the Hanmi
Intellectual Property in a manner that is inconsistent with the rights granted to Kinex under this Agreement; 
 (e) At no time during the
Agreement Term shall Hanmi, without Kinex’s prior written consent, enter into any other agreements regarding the Hanmi Intellectual Property, any Compound or any Licensed Product for the Field within the Territory; 

(f) The Data and information provided to Kinex or its Affiliates prior to the Effective Date relating to preclinical and clinical studies
related to the Compound HM30181A has been accurate in all respects and Hanmi has made no misrepresentation or omission in connection with such Data and information. Hanmi has also provided Kinex or its Affiliates with access to complete summaries of
all adverse events known to Hanmi relating to any Compound 
 (g) The Hanmi Intellectual Property listed in Schedule 1.2 is the
complete and exhaustive list of all current intellectual property and proprietary rights of Hanmi necessary for the Development and Commercialization of the Licensed Products in the Territory. 

5.3 Additional Agreements of Kinex. Kinex agrees that: 

(a) unless otherwise determined by Hanmi, Kinex shall use its best effort to include Hanmi, at no cost to Hanmi, as a joint applicant to the
Hong Kong government for the grant covering the Orascovery Program that will be applied for by Kinex. 

  
 33 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 ARTICLE 6 

PATENT MATTERS 
 6.1 Ownership of
Inventions. 
 (a) Except as otherwise provided in and subject to the terms of this Agreement, as between the Parties: 

(i) Hanmi shall have and retain all right, title and interest in or Control over, as applicable, all Intellectual Property (and
Patent Rights arising thereunder): (i) existing, owned or Controlled by it on the Effective Date, subject to the licenses and other rights for the specified Territory granted to Kinex under this Agreement both within and outside the Territory;
or (ii) which is discovered, made, first conceived, reduced to practice or generated under this Agreement both within and outside the Territory as a result of Development or otherwise during the Agreement Term solely by Hanmi employees, agents,
or other persons acting under or pursuant to its authority; provided, however, during the Agreement Term, Kinex shall have the right to use such Intellectual Property developed solely by Hanmi employees, agents, or other persons acting under
or pursuant to its authority within the Territory, free of charge, in collaborating with Hanmi in relation to the Orascovery Program. In the event Kinex wishes to use such Intellectual Property developed solely by Hanmi within the Territory for any
purpose unrelated to the Orascovery Program, outside the Territory for any purpose, or after the expiration of the Agreement Term, Hanmi and Kinex shall discuss in good faith on the permissibility, scope, terms, and conditions of such use. 

  
 34 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (ii) Kinex shall have and retain all right, title and interest in or Control
over all Intellectual Property (and Patent Rights arising thereunder) which is discovered, made, first conceived, reduced to practice or generated under this Agreement both within and outside the Territory as a result of Development or otherwise
during the Agreement Term, solely by Kinex’s employees, agents, or other persons acting under or pursuant to its authority; provided, however, during the Agreement Term, Hanmi shall have the right to use such Intellectual Property
developed solely by Kinex employees, agents, or other persons acting under or pursuant to its authority within the Territory, free of charge, in collaborating with Kinex in relation to the Orascovery Program. In the event Hanmi wishes to use such
Intellectual Property developed solely by Kinex within the Territory for any purpose unrelated to the Orascovery Program, outside the Territory for any purpose, or after the expiration of the Agreement Term, Kinex and Hanmi shall discuss in good
faith on the permissibility, scope, terms, and conditions of such use. 
 (iii) Hanmi and Kinex shall jointly own all right,
title and interest in or Control over all Intellectual Property (and Patent Rights arising thereunder) which is discovered, made, first conceived, reduced to practice or generated under this Agreement both within and outside the Territory as a
result of Development or otherwise during the Agreement Term jointly by Hanmi and Kinex employees, agents, or other persons acting under or pursuant to their authority (“Jointly Owned Intellectual Property”). With respect to Jointly
Owned Intellectual Property, both Parties shall have the right to use such Intellectual Property within the Territory, free of charge, subject to the terms of this Agreement. Hanmi shall have the sole right to use the Jointly Owned Intellectual
Property in all countries outside the Territory without accounting or payment to Kinex. For the avoidance of doubt, the right, title and interest of a Party in, or control of, the Jointly Owned Intellectual Property shall survive the termination and
expiration of this Agreement. 

  
 35 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) Employees and Agents. Each of Hanmi and Kinex shall require all of its and its
Affiliates’ employees to assign all inventions and corresponding patent applications that are discovered, made, first conceived, reduced to practice or generated by such employees during the Agreement Term to Hanmi and/or Kinex according to the
ownership principles described in Section 6.1(a) and subject to the laws of the country of employment. Each Party shall use Commercially Reasonable Efforts to require any Third Parties working on the Phase I Clinical Study or any Development
under the Agreement or who receive materials relating to a Licensed Product or Know-How from a Party, to assign or grant a sublicensable exclusive license on a fully paid-up, royalty-free basis to all inventions and corresponding Patent Rights that
are developed, made or conceived by such Third Parties during the Agreement Term to Hanmi and/or Kinex according to the ownership principles described in Section 6.1(a). 

6.2 Filing and Maintenance. 
 (a)
Hanmi Patent Rights. Hanmi shall have the sole right to file and maintain the Hanmi Patent Rights in Hanmi’s name within and outside the Territory, by retaining patent counsel selected by Hanmi and shall be responsible for the payment of
all costs and fees relating to patent filing and maintenance. Hanmi agrees to keep Kinex informed of the course of patent application or other proceedings and to furnish Kinex, per its request, with copies of office actions received by Hanmi from
any Regulatory Authority within or outside the Territory concerning Hanmi Patent Rights. Hanmi shall also have the first right to file and maintain all Jointly Owned Intellectual Property in all countries outside the Territory. Kinex may request
that Hanmi pay maintenance fees or make additional patent application filings within the Territory for the Hanmi Intellectual Property. If Hanmi elects not to pay such fees or make such filings within a period of thirty (30) days from the date
of such request, Kinex shall have the right to pay the fees or make the filing in the name of and as agent for Hanmi. In such event, Kinex shall be responsible for the payment of all costs and fees relating to such patent filing and maintenance.

 (b) Kinex Patent Rights. Kinex shall have the sole right to file and maintain the Kinex Patent Rights in Kinex’s name or the
name of its Affiliates within and outside the Territory by retaining patent 

  
 36 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
counsel selected by Kinex and shall be responsible for the payment of all costs and fees relating to patent filing and maintenance. Kinex agrees to keep Hanmi informed of the course of patent
application or other proceedings and to furnish Hanmi, per its request, with copies of office actions received by Kinex from any Regulatory Authority outside the Territory concerning Kinex Patent Rights. Kinex or its Affiliates shall also have the
first right to file and maintain all Jointly Owned Intellectual Property in the Territory. Kinex hereby grants a right of first refusal to Hanmi for any Kinex Patent Rights required by the Licensed Products for which Kinex intends to grant any right
or license outside the Territory and outside any territories licensed to its Affiliates. Kinex shall provide Hanmi with written notice of the terms on which Kinex proposes to license such Kinex Patent Rights outside the Territory and outside any
territories licensed to its Affiliates, and Hanmi shall have ninety (90) days from the date of receipt of such written notice to send a written reply to Kinex indicating its desire to license such Kinex Patent Rights on the terms contained in
Kinex’s written notice. If Hanmi does not respond within the ninety (90) days, Kinex shall be free to license such Kinex Patent Rights to third parties outside the Territory and outside any territories licensed to its Affiliates on the
terms and conditions contained in the written notice sent to Hanmi. 
 (c) The responsible Party under this Section 6.2 shall solicit
the other Party’s review of the nature and text of any patent applications within and outside the Territory in reasonably sufficient time prior to the filing thereof, and the responsible Party shall take into account the other Party’s
reasonable comments related thereto. Each Party shall execute all documents and take all actions as are reasonably requested by the other Party with respect to any filings and registrations. 

6.3 Third Party Infringement. 
 (a) Each
Party shall promptly give the other Party notice of any actual or suspected infringement by a Third Party in the Territory or outside the Territory of any patent included in the Hanmi Patent Rights and Kinex Patent Rights relating to the Licensed
Products or Jointly Owned Intellectual Property (collectively, the “Parties’ Patent Rights”), which comes to such Party’s attention. 

  
 37 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) Infringement of Parties’ Patent Rights within the Territory. The Party whose
Patent Rights have been infringed upon shall have the first right, but not the obligation, to initiate and prosecute such legal action in the Territory at its own cost and expense and in its own name, or to control the defense of any declaratory
judgment action in the Territory relating to its Patent Rights, and such Party shall provide the other Party with reasonable notice of any such action it commences and keep the other Party reasonably informed of any significant developments in such
action; provided, however, for infringement of Jointly Owned Intellectual Property within the Territory, any legal action shall be taken jointly by Hanmi and Kinex and the cost and expenses for such legal action shall be shared equally. Each
Party shall render, at its expense, all assistance reasonably requested in connection with any action taken by the other Party or to prevent such infringement (including reasonable attorneys’ fees). However, the control of such action,
including whether to initiate any legal proceeding and/or the settlement thereof, shall be under the control of the Party whose Patent Rights have been infringed; provided that such Party shall not settle any such claim or proceeding in a
manner that adversely affects the other Party’s rights under this Agreement or rights in Patent Rights or which results in any monetary payment by or financial loss to such other Party, without the other Party’s prior written consent,
which consent shall not be unreasonably withheld. 
 (c) If a Party elects not to initiate and prosecute an infringement or defend a
declaratory judgment action in the Territory as provided in Section 6.3(b) within sixty (60) days after having become aware of such potential infringement, then Hanmi and Kinex shall discuss and agree on whether to take such action that is
reasonably necessary and appropriate to terminate or prevent such infringement, including instituting an infringement proceeding and whether such action will be taken jointly by Hanmi and Kinex (in which case the cost and expense shall be shared
equally) or by the other Party on its own (in which case the cost and expense shall be borne by such other Party), provided, however, that even if it is agreed that the other Party is to take such action on its own, such other Party shall not
enter into any settlement or compromise of any claim relating to the subject Patent Rights licensed hereunder or which results in any material monetary payment by or financial loss to the Party that owns the Patent Rights, without such Party’s
prior written consent, which consent shall not be unreasonably withheld. 

  
 38 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (d) Infringement of Parties’ Patent Rights outside the Territory. The Party whose
Patent Rights have been infringed shall have the sole right to initiate and prosecute any legal action outside the Territory with respect to such Patent Rights relating to the Licensed Products at its own cost and expense and in its own name, or to
control the defense of any declaratory judgment action outside the Territory relating to such Patent Rights; provided, however, for infringement of Jointly Owned Intellectual Property outside the Territory, any legal action shall be taken
jointly by Hanmi and Kinex and the cost and expenses for such legal action shall be shared equally. Notwithstanding, the Party whose Patent Rights are not the subject of infringement shall be given an opportunity to participate in the prosecution or
other legal action and if such other Party agrees to participate, then the cost and expenses for such legal action shall be shared equally. 

(e) For any legal action or defense contemplated by this Section 6.3 within or outside the Territory, the Parties will cooperate fully
and will provide each other with any information or assistance that either reasonably may request. Title to or responsibility for any recovery, award, damages, settlement, future royalty payments to Third Parties or other liability as a result of
any such action or settlement shall be determined based on the cost responsibility principle set forth in Section 6.3(b), (c) and (d). 
 6.4
Third Party Intellectual Property. 
 (a) Infringement of Third Party Intellectual Property within the Territory. In the event
that a Party becomes aware of any claim that the practice by either Party of the Parties’ Patent Rights infringes the intellectual property rights of any Third Party in the Territory, such Party shall promptly notify the other Party. The
Parties shall thereafter discuss the situation, and to the extent reasonably necessary, attempt to agree on a course of action. 

  
 39 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) Regardless of who initiates and defends such legal action in the Territory, the Parties
agree that in the event such legal action arises out of a claim solely relating to Hanmi Patent Rights, then the cost for such legal action and all damages awarded or settlement payments made (including future royalty or similar payments) to such
Third Party shall be for Hanmi’s account. If such legal action arises out of claim solely relating to Kinex Patent Rights, then the cost for such legal action and all damages awarded or settlement payments made (including future royalty or
similar payments) to such Third Party shall be for Kinex’s account. For legal action relating to Jointly Owned Intellectual Property, the cost for such legal action and all damages awarded or settlement payments made (including future royalty
or similar payments) to such Third Party shall be shared equally by the Parties. 
 (c) Infringement of Third Party Intellectual Property
outside the Territory. The Party whose Patent Rights are the subject of an infringement claim outside the Territory shall have the sole right, but not the obligation to defend any action related to the intellectual property rights outside the
Territory of any Third Party or to initiate and prosecute legal action outside the Territory related to the intellectual property rights of any Third Party at its own cost and expense and in its own name; provided, however, for claims of
infringement by Jointly Owned Intellectual Property outside the Territory, any legal action shall be taken jointly by Hanmi and Kinex and the cost and expenses for such legal action shall be shared equally. Notwithstanding, the Party whose Patent
Rights are not the subject of infringement shall be given an opportunity to participate in the defense or other legal action and if such other Party agrees to participate, then the cost and expenses for such legal action shall be shared equally.
Each Party shall render, at its own expense, all assistance reasonably requested in connection with any action taken by the other Party. However, the control of such action, including whether to initiate any legal proceeding and/or the settlement
thereof, shall solely be under the control of such other Party. Title to or responsibility for any recovery, award, damages, settlement, future royalty payments to Third Parties or other liability as a result of any such action or settlement shall
be determined based on the cost responsibility principal set forth in Section 6.4(c). 

  
 40 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 6.5 Patent Term Extensions. The Parties shall cooperate with each other in obtaining patent term
extensions or restorations or supplemental protection certificates or their equivalents in the Territory where applicable and where desired by Kinex. Elections with respect to obtaining such extension or supplemental protection certificates shall be
made in the same manner and with the same relative priorities between the Parties as is applicable to the prosecution and maintenance of Patent Rights pursuant to Section 6.2. 

6.6 Patent Marking. Kinex shall mark, and shall require its Affiliates and sublicensees to mark, all Licensed Products sold or distributed pursuant to
this Agreement in accordance with the applicable patent statutes or regulations in the country or countries of manufacture and/or sale thereof. 

ARTICLE 7 

CONFIDENTIALITY AND PUBLICITY 
 7.1
Non-Disclosure and Non-Use Obligations. All Proprietary Information disclosed by one Party to the other Party hereunder shall be maintained in confidence and shall not be disclosed to any Third Party or used for any purpose except as
expressly permitted herein without the prior written consent of the Party that disclosed the Proprietary Information to the other Party during the term of this Agreement and for a period of ten (10) years thereafter. The foregoing nondisclosure
and non-use obligations shall not apply to the extent that such Proprietary Information: 
 (a) is known by the receiving Party at the time
of its receipt, and not through a prior disclosure by the disclosing Party, as documented by records; 
 (b) is or becomes properly in the
public domain or knowledge without breach by either Party; 
 (c) is subsequently disclosed to a receiving Party by a Third Party who may
lawfully do so and is not under an obligation of confidentiality to the disclosing Party; or 
 (d) is developed by the receiving Party
independently of Proprietary Information received from the disclosing Party, as documented by records. 

  
 41 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 7.2 Permitted Disclosure of Proprietary Information. Notwithstanding Section 7.1, a Party
receiving Proprietary Information of another Party may disclose such Proprietary Information: 
 (a) to governmental or other regulatory
agencies in order to obtain patents pursuant to this Agreement, or to gain approval to conduct Clinical Studies or to market a Licensed Product, but such disclosure may be only to the extent reasonably necessary to obtain such patents or
authorizations and in accordance with the terms of this Agreement or as otherwise requested by the Regulatory Authorities; 
 (b) by Kinex
to its agents, consultants, sublicensees or Affiliates in connection with the Development or Commercialization, or to otherwise enable Kinex to fulfill its obligations and responsibilities under this Agreement, on the condition that such entities
agree to be bound by confidentiality obligations consistent with this Agreement; or 
 (c) if required to be disclosed by law or court
order; provided that notice is promptly delivered to the non-disclosing Party in order to provide an opportunity to challenge or limit the disclosure obligations. 

(d) Certain Disclosures. Except as set forth in this Agreement or as required by law, neither Party shall make any press release or
other public announcement or other public disclosure to a Third Party concerning the existence of or terms of this Agreement, the subject matter of this Agreement or the activities contemplated hereunder, without the prior written consent of the
other Party, which consent shall include agreement upon the nature and text of such release, announcement, or other disclosure, and shall not be unreasonably withheld or delayed. Each Party agrees to provide to the other Party a copy of any such
press release or other public announcement or disclosure as soon as reasonably practicable under the circumstances prior to its scheduled release. Each Party shall have the right to expeditiously (but in any event within forty eight (48) hours)
review and recommend changes to any such press release or other 

  
 42 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
public announcement or disclosure; provided, however, that such right of review and recommendation shall only apply for the first time that specific information is to be disclosed, and
shall not apply to the subsequent disclosure of substantially similar information that has previously been disclosed unless there have been material developments relating to any Licensed Product since the date of the previous disclosure;
provided, further, that each Party shall provide to the other Party reasonable advance notice of any such subsequent disclosure. Without limiting the generality of any of the foregoing, it is understood that the Parties or their Affiliates
may make disclosure of this Agreement and the terms hereof in accordance with the rules and regulations of the CSRC, the US Securities and Exchange Commission, other governmental authority, or securities exchange, may file this Agreement as an
exhibit to any filing with the CSRC, the US Securities and Exchange Commission, other governmental authority, or securities exchange, and may distribute any such filing in the ordinary course of its business, provided, further, that to the
maximum extent allowable by the rules and regulations of the CSRC, the US Securities and Exchange Commission, other governmental authority, or securities exchange, and except as required by applicable Laws, Hanmi and Kinex shall seek to redact any
confidential information set forth in such filings, and each Party shall provide a draft of the redacted version of this Agreement to the other Party no less than five (5) Business Days prior to filing with the CSRC, the US Securities and
Exchange Commission, other governmental authority, or securities exchange, and give reasonable consideration to the other Party’s comments regarding any proposed redaction. 

7.3 Publications. Kinex shall not submit for written or oral publication any manuscript, abstract or the like relating to any Compound or any Licensed
Product, without the prior approval or written request of Hanmi. If Kinex desires to submit such publication, it shall first deliver to Hanmi, for Hanmi’s prior written consent, the proposed publication or an outline of the oral disclosure at
least sixty (60) days prior to planned submission or presentation. 
 7.4 Publicity: Except as otherwise provided in this Agreement or required
by law or regulation, no Party will originate any news release or other public announcement, written or oral, whether in the public press, stockholders’ reports or otherwise, relating to this Agreement or to any Sublicense under this Agreement,
or to the performance under this Agreement or under any Sublicense under this Agreement, without the prior written approval of the other Party, which approval will not be unreasonably withheld or delayed: provided that the foregoing shall not
restrict disclosures made in connection with any filing of information or materials with a stock exchange, government authority, the CSRC, the US Securities and Exchange Commission, or any stockholders’ letter to private investors. 

  
 43 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 ARTICLE 8 

TERM AND TERMINATION 
 8.1 Term and
Expiration. This Agreement shall be binding on the Parties as of the Effective Date. Thereafter, unless terminated earlier pursuant to Section 8.2 below, this Agreement shall extend for a period which may expire upon the earliest to occur
of either (i) the expiration of the last of the Hanmi Patent Rights in the Territory or (ii) invalidation of substantially all of the Hanmi Patent Rights in the Territory (the “Agreement Term”). Notwithstanding the
foregoing, after the occurrence of (i) or (ii) above, the Agreement Term shall automatically be extended for consecutive one (1) year periods subject to the same terms and conditions set forth herein (unless agreed otherwise) unless
either Party gives written notice of its intention not to extend the Agreement Term: (i) at least ninety (90) days prior to the expiration date of the Hanmi Patent Rights; or (ii) as soon as practically possible in the case of an
invalidation claim; and (iii) at least ninety (90) days prior to the then current expiration date of the Agreement thereafter. 
 8.2 Early
Termination of Agreement Term. 
 (a) Termination by Agreement. 

This Agreement may be terminated in whole or in part upon mutual written agreement of the Parties. 

  
 44 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) Termination by Kinex. 

Kinex may terminate in whole or in part this Agreement in its sole discretion upon not less than six (6) months prior written notice of
termination provided any time after the Effective Date (provided, however, that no such termination shall be effective until the Completion of any then Ongoing Clinical Studies). The cost involved during the six (6) months on top of
completing the Ongoing Clinical Studies will also be borne by Kinex. In addition, if any milestone is met per the Clinical Studies prior to the final termination date, Kinex will also be responsible for the milestone payment. 

(c) Termination by Either Party. 

Either Party may, without prejudice to any other remedies available to it under this Agreement or at law or in equity,
terminate this Agreement prior to expiration of the Agreement Term in the event that any of the following occurs: 
 (i) The
other Party (as used in this subsection, the “Breaching Party”) shall have materially breached or defaulted in the performance of any of its material obligations hereunder (including a breach of the representations and warranties
set forth in this Agreement), and has not cured such breach within (i) thirty (30) days after notice of such breach is provided to the Breaching Party in case the breach is a non-payment of any amount due under this Agreement that is not
being disputed in good faith (which shall be deemed a material breach of a material obligation) or (ii) sixty (60) days after notice of such breach is provided to the Breaching Party for other cases of breach (or, if such default cannot be
cured within such sixty (60) day period, if the Breaching Party does not commence and diligently continue actions to cure such default during such sixty (60) day period). The termination shall become effective at the end of the
(i) thirty (30) day period in case the breach is a non-payment of any amount due under this Agreement that is not being disputed in good faith if the Breaching Party has not cured such breach by such date, or (ii) for other cases of
breach, sixty (60) day period unless (a) the 

  
 45 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
Breaching Party cures such breach during such sixty (60) day period, or (b) if such breach is not susceptible to cure within such sixty (60) day period, the Breaching Party has
commenced and is diligently pursuing a cure (unless such breach, by its nature, is incurable, in which case the Agreement may not be terminated unless the Breaching Party fails to use its best commercially reasonable efforts to prevent a similar
subsequent breach). The right of either Hanmi or Kinex to terminate this Agreement as provided in this Section 8.2(c)(i) shall not he affected in any way by such Party’s waiver or failure to take action with respect to any previous breach
or default. 
 (ii) The other Party stops or suspends payment of all or a class of its debts, becomes insolvent or sells or
parts with possession of the whole or a major part of its assets or major undertaking. 
 (iii) An application or order is
made, proceedings are commenced, a resolution is passed or proposed in a notice of meeting or an application to a court or other steps are taken (other than frivolous or vexatious applications, proceedings, notice or steps) for the winding up or
dissolution of the other Party or for it to enter an arrangement, compromise or composition with or assignment for the benefit of its creditors, a class of them or any of them. 

(iv) The Parties agree in writing to terminate this Agreement. 

8.3 Effect of Expiration or Termination; Survival. 

(a) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination, including all accrued payment obligations arising under Article 4 hereof. In addition to any other provisions of this Agreement which by their terms continue after the expiration of this Agreement, the provisions of
Articles3.3(h),6, 7, 9 and 10 shall survive the expiration or termination of this Agreement and shall continue in effect after the date of expiration or termination for the longer of (i) five (5) years or (ii) the respective periods
specified therein. Any expiration or early termination of this Agreement shall be without prejudice to the rights of any Party 

  
 46 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
against the other accrued or accruing under this Agreement prior to termination. Except as expressly set forth herein, the rights to terminate as set forth herein shall be in addition to all
other rights and remedies available under this Agreement, at law, or in equity, or otherwise. 
 (b) Payments of amounts owing to Hanmi
under this Agreement as of its expiration or termination shall be due and payable either (i) to the extent such amounts can be calculated and a fixed sum determined at the time of expiration or termination of this Agreement, thirty
(30) days after the date of such expiration or termination, or (ii) to the extent such amounts cannot be calculated and a fixed sum determined at the time of expiration or termination of this Agreement, thirty (30) days after the date
at which such amounts can be calculated and a fixed sum is mutually determined. 
 (c) Subject to the payment of all amounts required
hereunder, Kinex and its Affiliates shall have the right to sell or otherwise dispose of the stock of any Licensed Product subject to this Agreement on hand or in process of manufacture as of the expiration or termination of this Agreement. Within
thirty (30) days after the effective date of termination or expiration of this Agreement, Kinex shall notify Hanmi of the amount of each Licensed Product Kinex and its Affiliates then have on hand or in the process of manufacture and shall have
the right to sell in the Territory, its remaining stock of Licensed Product until all of it is sold; provided, however, the terms and conditions of this Agreement shall apply to such Licensed Product so sold. Hanmi hereby grants a
non-exclusive license to Kinex as necessary to sell such Licensed Product in the Territory, subject to payment of all related amounts due under this Agreement. Any remaining quantities of Licensed Product not sold, at Kinex’s election, may be
(i) destroyed by Kinex at Kinex’s cost, (ii) sold to Hanmi at Kinex’s procurement cost for such Licensed Product, or (iii) sold to customers in the Territory. 

(d) Upon the termination or expiration of this Agreement, the following shall also be applicable: (i) at Hanmi’s request, Kinex
shall promptly transfer and return to Hamni copies of all Data, reports, records and materials in Kinex’s possession or control that relate to all Compounds or Licensed Products and return to Hanmi all relevant records and materials in
Kinex’s possession or control 

  
 47 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
containing Proprietary Information of Hanmi (provided that Kinex may keep one copy of such Proprietary Information of Hanmi for archival purposes only); (ii) Kinex shall transfer to
Hanmi ownership of any INDs, Regulatory Approvals, Drug Approval Applications and any other regulatory filings or submissions made or filed for any Licensed Product by Kinex or its designees; (iii) Hanmi shall promptly return to Kinex all
relevant records and materials in Hanmi’s possession or control containing Proprietary Information of Kinex (provided that, Hanmi may keep one copy of such Proprietary Information of Kinex for archival purposes only); and (iv) all
Sublicenses between Kinex and Third Parties shall survive the termination or expiration of this Agreement and shall be assigned by Kinex to Hanmi. 

(e) If Kinex becomes insolvent or contemplates the filing for bankruptcy under bankruptcy laws of Hong Kong prior to Regulatory Approval or
comparable laws providing for liquidation or other debtor protection of Kinex, Kinex shall immediately inform Hanmi in writing of such situation, in which case Hanmi shall have the right to buy back all rights under this Agreement for $***. If Kinex
files for bankruptcy or other debtor protection under the bankruptcy laws of Hong Kong after Regulatory Approval, Hanmi would have the right to buy back all rights under this Agreement at a price equal to the fair market value and Kinex shall
cooperate with Hanmi to ensure that such buy back is consummated, subject to the applicable laws. Fair market value would be determined by a Hong Kong based investment banking firm agreed to by Hanmi and Kinex and approved by the bankruptcy court.

 ARTICLE 9 

INDEMNIFICATION AND INSURANCE 
 9.1
Indemnity. For purposes of this Article 9, “Hanmi Indemnified Parties” refers to Hanmi, its Affiliates and the officers, directors, employees, shareholders, agents and successors and assigns of Hanmi and its Affiliates,
and “Kinex Indemnified Parties” refers to Kinex, its Affiliates and officers, directors, employees, shareholders, agents and successors and assigns of Kinex and its Affiliates. 

  
 48 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 9.2 Kinex Indemnification. Kinex shall defend the Hanmi Indemnified Parties from and against all
suits, claims, actions, demands, complaints, lawsuits or other proceedings, (collectively, “Claims”), that are brought by a Third Party, and shall indemnify and hold harmless to the fullest extent permitted by law the Hanmi
Indemnified Parties from and against any and all Losses, that arise out of or are attributable to, (i) Kinex’s negligence, recklessness or willful misconduct in exercising or performing any of its rights or obligations under this
Agreement; or (ii) a material breach by Kinex of any of its obligations, representations, warranties or covenants under this Agreement within the Territory; provided, however, that Kinex shall not be obligated under this
Section 9.2, to the extent it is shown by evidence acceptable in a court of law having jurisdiction over the subject matter and meeting the appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing on
the part of Hanmi. 
 9.3 Hanmi Indemnification. Hanmi shall defend the Kinex Indemnified Parties from and against all Claims, in each case that are
brought by a Third Party, and shall indemnify and hold harmless to the fullest extent permitted by law the Kinex Indemnified Parties from and against any and all Losses that arise out of such Claims that are attributable to, (i) Hanmi’s
negligence, recklessness or willful misconduct in exercising or performing any of its rights or obligations under this Agreement; or (ii) a material breach by Hanmi of any of its obligations, representations, warranties or covenants under this
Agreement outside the Territory provided, however, that Hanmi shall not be obligated under this Section 9.3, to the extent it is shown by evidence acceptable in a court of law having jurisdiction over the subject matter and meeting the
appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing on the part of Kinex. 
 9.4 Indemnification
Procedure. 
 (a) Each Party shall promptly notify the other Party in writing of any Claim. Concurrent with the provision of notice pursuant to this
Section 9.4(a), the Indemnified Party shall provide to the other Party copies of any complaint, summons, subpoena or other court filings or correspondence related to such Claim and will give such other information with respect thereto as the
other Party shall reasonably 

  
 49 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
request. The Indemnifying Party and Indemnified Party shall meet to discuss how to respond to such Claim. Failure to provide prompt notice shall not relieve any Party of the duty to defend or
indemnify unless such failure materially prejudices the defense of any matter. Each Party agrees that it will take reasonable steps to minimize the burdens of the litigation on witnesses and on the ongoing business of the Indemnified Parties
including making reasonable accommodations to witnesses’ schedules when possible and seeking appropriate protective orders limiting the duration and/or location of depositions. 

(b) Should either Party dispute that any Claim or portion of a Claim (“Disputed Claim”) of which it receives notice pursuant to
Section 9.4(a), is an indemnified Claim, it shall so notify the other Party providing written notice in sufficient time to permit such other Party to retain counsel and timely appear, answer and/or move in any such action. In such event, such
other Party shall defend against such Claim; provided, however, that such other Party shall not settle any Claim which it contends is an indemnified Claim without providing the Indemnifying Party ten (10) Business Days’ notice prior
to any such settlement and an opportunity to assume the defense and indemnification of such Claim pursuant to this Agreement. If it is determined that a Disputed Claim is subject to indemnification, the Indemnifying Party will reimburse the costs
and expenses, including reasonable attorneys’ fees, of the Indemnified Party. 
 9.5 Settlement of Indemnified Claims. The Indemnifying Party
under Sections 9.2 or 9.3, as applicable, shall have the sole authority to settle any Indemnified Claim without the consent of the other Party; provided, however, that an Indemnifying Party shall not, without the written consent of the
other Party, as part of any settlement or compromise (i) admit to liability on the part of the other Party; (ii) agree to an injunction against the other Party; or (ii) settle any matter in a manner that separately apportions fault to
the other Party. The Parties further agree that as part of the settlement of any Indemnified Claim, an Indemnifying Party shall obtain a full, complete and unconditional release from the claimant on behalf of the Indemnified Parties. 

  
 50 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 9.6 Insurance. 

(a) Kinex shall maintain in the Territory, commencing as of the Effective Date, commercial general liability insurance (including coverage for product
liability, contractual liability, bodily injury, property damage and personal injury), in form and substance reasonably satisfactory to Hanmi and in accordance with reasonable industry standards, with minimum limits of $5,000,000 per occurrence or,
in case of Clinical Studies, $5,000,000 per occurrence during the period when such Clinical Studies are being conducted (the “Insurance”). If such Insurance is written on a claims-made form, it shall continue for three
(3) years following termination of this Agreement. The Insurance shall have retroactive date to or coinciding with the Effective Date. Notwithstanding the foregoing, Kinex may satisfy the foregoing obligation with respect to the Insurance
through self-insurance. 
 (b) Such Insurance shall insure against all liability arising out of the manufacture, use, sale, distribution, or marketing of
all Licensed Products in and for the Territory. During the Agreement Term, Kinex shall not permit such Insurance to be reduced, expired, materially amended or canceled during the period of the Insurance and/or the Agreement without reasonable prior
written notice that shall be sent by registered mail to Hanmi. Upon request Kinex shall provide certificates of insurance to Hanmi evidencing the coverage specified herein. 

(c) Except as expressly stated herein, a Party’s liability to the other is in no way limited to the extent of the Party’s insurance coverage. 

(d) The Insurance shall contain an explicit clause, stating that each Party and its insurer waive their rights of subrogation against the other Party and its
directors, employees and/or any one on its behalf with respect to the Insurance. Such waiver shall not apply in the event of a malicious act. 
 (e) The
Insurance shall be primary to any other insurance maintained by each Party and each Party hereby waives any claim or demand as to participation in any such other insurance. 

(f) The Insurance shall be valid in any location worldwide regarding the activities performed by each Party hereunder (including worldwide jurisdictions) for
any destination or lawsuit which will be served against the other Party. 

  
 51 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 9.7 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS
AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES, WHETHER BASED UPON A CLAIM OR ACTION OF
CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS
UNDER THIS ARTICLE. 
 ARTICLE 10 

MISCELLANEOUS 
 10.1 Force Majeure.
Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached the Agreement for failure or delay in fulfilling or performing any term of the Agreement during the period of time when such
failure or delay is caused by or results from events beyond the reasonable control of a Party, including fire, flood, earthquake, explosion, storm, blockage, embargo, war, acts of war (whether war be declared or not), terrorism, insurrection, riot,
civil commotion, strike, lockout or other labor disturbance, failure of public utilities or common carriers, act of God or act, omission or delay in acting by any governmental authority or the other Party. The affected Party shall notify the other
Party of such force majeure circumstances as soon as reasonably practicable. 
 10.2 Assignment. The Agreement may not be assigned or otherwise
transferred without the prior written consent of the other Party: provided, however, that either Party may assign this Agreement in 

  
 52 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
whole or in part to an Affiliate. In addition, Hanmi may assign this Agreement in connection with the transfer or sale of its business or all of its assets or in the event of a merger, or
consolidation upon prior written notice to the Kinex only if Hanmi warrants and ensures and the successor entity agrees to assume all (and not less than all) of the transferring Party’s responsibilities and obligations under this Agreement.
Notwithstanding, any assignment permitted under this Agreement shall not relieve the transferring Party of its responsibilities for performance of its obligations under this Agreement as a primary obligor. This Agreement shall be binding upon and
inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void. 
 10.3
Severability. In the event that any of the provisions contained in this Agreement are held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in
any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. In such event, the Parties covenant and agree to renegotiate any such term, covenant or application
thereof in good faith in order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid or unenforceable, it being the intent of the Parties that the basic
purposes of this Agreement are to be effectuated. 
 10.4 Notices. 

(a) Correspondence, reports, documentation, and any other communication in writing between the Parties in the course of ordinary implementation of this
Agreement (but not including any notice required by this Agreement) shall be in writing and delivered by hand, sent by e-mail, or by overnight express mail (e.g., FedEx) to any one
(1) representative designated by the Party which is to receive such written communication. 
 (b) Extraordinary notices and communications (including
but not limited to notices of termination, force majeure, material breach, change of address, or any other notices required by this 

  
 53 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
Agreement) shall be in writing and shall be deemed to have been given when delivered in person, or sent by overnight courier service (e.g., FedEx), postage prepaid, or by facsimile or
email confirmed by prepaid registered or certified air mail letter, return receipt requested, to the following addresses of the Parties (or to such other address or addresses as may be specified from time to time in a written notice), and shall be
deemed to have been properly served to the addressee upon receipt of such written communication, to the following addresses of the Parties: 

if to Kinex or Kinex US to: 

KINEX THERAPEUTICS (HK) LIMITED 

Hong Kong Address: 
 11/F, AXA
Centre 151 Gloucester Road 
 Hong Kong 

And 
 US Address: 

701 Ellicott Street 
 Buffalo, New
York 14203 
 USA 
 Attention:
Chief Executive Officer 
 Fax No.: +1-716-849-6651 

if to Hanmi to: 
 HANMI
PHARMACEUTICAL CO., LTD. 
 14, Wiryeseong-daero, Songpa-gu 

Seoul 138-724 
 South Korea 

Attention: Director, Clinical Development & Licensing 

Fax No.: +82-2-410-9278 

  
 54 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 or to such other address as the Party to whom notice is to be given may have furnished to the other Parties
in writing in accordance herewith. Any such communication shall be deemed to have been given when delivered if personally delivered or sent by email facsimile on a Business Day, upon confirmed delivery by nationally-recognized overnight courier if
so delivered, and on the third Business Day following the date of mailing if sent by registered or certified air mail. 
 10.5 Specific Performance.
Each of the Parties acknowledges and agrees that the other Party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in all material respects or otherwise are breached. Accordingly, and notwithstanding
anything herein to the contrary, each of the Parties agrees that the other Party shall be entitled to seek injunctive relief to prevent breaches of the provisions of this Agreement, and/or to enforce specifically this Agreement and the terms and
provisions hereof, in any action instituted in any court or tribunal having jurisdiction over the Parties and the matter, without posting any bond or other security, and that such injunctive relief shall be in addition to any other remedies to which
such Party may be entitled, at law or in equity. Any such action or proceeding shall be heard and determined in any court sitting in Singapore or other court of competent jurisdiction in the Territory, and the Parties hereto hereby irrevocably
submit to the exclusive jurisdiction of such courts in any such action or proceeding and irrevocably waive any defense of any inconvenient forum or alternative forum to the maintenance of any such action or proceeding, including any decision by such
court regarding the substantive issues involved in the underlying dispute. 
 10.6 Further Assurances. Each of the Parties shall take such further
actions as shall be necessary or desirable in order to effectuate the respective rights and obligations hereunder. 
 10.7 Applicable Law, Venue and
Dispute Resolution. This Agreement shall be governed by the laws of the State of New York. The United Nations Convention on Contracts for the International Sale of 

  
 55 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 
Goods shall not apply in any action, suit or proceeding arising out of or relating to this Agreement. Except as provide in Section 10.5, with regard to actions of specific performance, all
disputes which arise in connection with this Agreement and its interpretation shall be settled in amicable way between the Parties. If the dispute cannot be settled in an amicable manner, it will be settled by arbitration to be held in Republic of
Singapore in conformity with commercial arbitration rules of the International Chamber of Commerce. The award rendered by arbitration shall be final and binding upon the Parties hereto. 

10.8 Entire Agreement. This Agreement, including the exhibits and schedules hereto, contains the entire understanding of the Parties with respect to
the subject matter. All express or implied agreements and understandings, either oral or written, heretofore made, including any offering letters, letters of intent, or term sheets, are expressly superseded by this Agreement. This Agreement may be
amended, or any term hereof modified, only by a written instrument duly executed by all Parties hereto. 
 10.9 Independent Contractors. It is
expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Party shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of such other Party. 

10.10 Waiver. The waiver by a Party hereto of any right hereunder or the failure to perform or of a breach by another Party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 
 10.11 Headings;
References. The captions to the several Articles and Sections hereof are not a part of the Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to
an Article, Exhibit, Schedule or Section shall, unless otherwise specifically provided, be to an Article, Exhibit, Schedule or Section of this Agreement. The words “including”, “includes” and “such as” are used in their
non-limiting sense and have the same meaning as “including without limitation” and “including but not limited to.” “Hereunder” and “hereto” means under or pursuant to any provision of this Agreement. 

  
 56 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 10.12 Interpretation. Both Parties have had the opportunity to have this Agreement reviewed by an
attorney; therefore, neither this Agreement nor any provision hereof shall be construed against the drafter of this Agreement. 
 10.13 Counterparts.
The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to the Agreement transmitted by fax, by email in “portable
document format” (“pdf”) or by any other electronic means intended to preserve the original graphic and pictorial appearance of the Agreement shall have the same effect as physical delivery of the paper document bearing an original
signature. 
 10.14 No Third Party Beneficiaries. Except as specifically set forth herein, none of the provisions of this Agreement shall be for the
benefit of or enforceable by any Third Party, including any creditor of either Party hereto. No such Third Party shall obtain any right under any provision of this Agreement or shall by reasons of any such provision make any claim in respect of any
debt, liability or obligation (or otherwise) against either Party hereto. 
 10.15 Guarantee by Kinex US. 

(a) Kinex US guarantees to Hanmi the due and punctual performance by Kinex of each and all of the obligations, duties and undertakings of
Kinex under and pursuant to this Agreement when and if such obligations, duties and undertakings shall become due and performable according to the terms of this Agreement to the extent permitted by the applicable laws in the event that Kinex shall
fail or be unable to perform such obligations, duties and undertakings for any reason whatsoever. 
 (b) Without prejudice to the above, if
Kinex shall in any respect fail to perform or commit any breach of its obligations, duties and/or undertakings hereunder, then Kinex US shall fully indemnify Hanmi against all losses, damages, costs and expenses which may be incurred by Hanmi by
reason of any omission or default on the part of Kinex in performing and observing this Agreement. 

  
 57 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (c) This guarantee is a continuing guarantee and, accordingly, shall remain in operation
until all obligations, warranties, duties and undertakings now or hereafter to be carried out or performed by Kinex under this Agreement shall have been satisfied or performed in full and is in addition to and not in substitution for any other right
Hanmi may have at law or in equity and may be enforced without first having taken any steps or proceedings against Kinex. 
 (d) Kinex US
hereby agrees that Hanmi and Kinex may amend or revise this Agreement, and this guarantee shall remain valid to the amendment or revisions referred hereto. The obligations of Kinex US shall not be effected by any amendment or revision of this
Agreement. 
 (e) Kinex US undertakes not to raise any dispute on any claim made by Hanmi under this guarantee. 

(f) In addition, Kinex US covenants and agrees that it shall not sell a Controlling Interest in Kinex while Kinex is the licensee under this
Agreement. For purposes of the foregoing, a “Controlling Interest” shall mean legal or beneficial ownership of 50% or more of the voting power of the outstanding securities of Kinex. Any sale of a Controlling Interest in Kinex while Kinex
is the licensee under this Agreement shall require the prior written consent of Hanmi and Hanmi shall not withheld its approval for more than twenty one (21) days without reasonable ground. If a Liquidity Event occurs during this Agreement, the
conduct or result in such Liquidity Event shall in no way affect the validity, enforceability or maintenance of all provisions of this Agreement. 

(g) Nothing contained in this Section 10.15 shall prohibit the assignment of this Agreement by Kinex to Kinex US or its Affiliates 

  
 58 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above. 

 

			
	KINEX THERAPEUTICS (HK) LIMITED
		
	By:	 	  

	Name:	 	Johnson YN Lau
	Title:	 	Chief Executive Officer
	
	HANMI PHARMACEUTICAL CO., LTD.
		
	By:	 	  

	Name:	 	Gwan Sun Lee
	Title:	 	President and CEO
	
	KINEX PHARMACEUTICALS INC. (only with respect to Section 10.15)
		
	By:	 	  

	Name:	 	Johnson YN Lau
	Title:	 	Chief Executive Officer

  
 59 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

			
	SCHEDULE 1.1	  	DIAGRAM OF COMPOUND
		
	SCHEDULE 1.2	  	HANMI INTELLECTUAL PROPERTY
		
	SCHEDULE 1.3	  	AMENDMENT AGREEMENT

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 SCHEDULE 1.1 

DIAGRAM OF COMPOUND HM30181A 
 *** 

*** 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 SCHEDULE 1.2 

HANMI INTELLECTUAL PROPERTY 
 Table 1.
List of the Hanmi Intellectual Property in China 
  

											
	 Patent

Type
	 	 Title
	 	 Country
	 	 Status
	 	 Application #

(Parent Filing or
 Application
Date)
	 	 Publication #

(Date of
 publication)

	 ***
	 	***	 	***	 	***	 	***	 	***
	 ***
	 	***	 	***	 	***	 	***	 	***
	 ***
	 	***	 	***	 	***	 	***	 	***

  

	*	Currently, KR2012-0145603 is not entered into national phase yet. 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 SCHEDULE 1.3 

AMENDMENT AGREEMENT 
 THIS
AMENDMENT AGREEMENT (this “Amendment Agreement”) is made and entered into as of June 28, 2013 (“Effective Date”), by and between KINEX THERAPEUTICS (HK) LIMITED, a corporation organized and existing
under the laws of Hong Kong and having its principal office at 11/F, AXA Centre, 151 Gloucester Road, Hong Kong (“Kinex”) and HANMI PHARMACEUTICAL CO., LTD., a publicly traded company existing under the laws of South
Korea and having its principal office at 14, Wiryeseong-daero, Songpa-gu, Seoul, 138-724 South Korea (“Hanmi”). 

WITNESSETH: 

WHEREAS, Hanmi owns or Controls the Hanmi Intellectual Property and is developing Compounds for improved absorption for oral drug
dosing; 
 WHEREAS, Hanmi is currently licensing the Hanmi Intellectual Property to Kinex Therapeutics (HK) Limited, a Hong Kong
corporation and a wholly owned subsidiary of Kinex Pharmaceuticals, Inc., previously known as Kinex Pharmaceuticals, LLC (“Kinex US”), for the territory of Mainland China (“China License”); 

WHEREAS, Hanmi has previously licensed the Hanmi Intellectual Property in other territories to Kinex US (“Kinex US License”);
and 
 WHEREAS, according to the China License, Hanmi and Kinex agree to enter into this Amendment Agreement. 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 NOW, THEREFORE, in consideration of the mutual representations, warranties and
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 All capitalized terms used in this Amendment Agreement and not defined herein, shall have the meaning ascribed to them in the China
License. 
 ARTICLE 2 

AMENDMENT TO ARTICLE 4 OF THE CHINA LICENSE 

In accordance with the China License, Hanmi and Kinex agree that Section 4.2 of the China License shall be deleted in its entirety and
replaced with portions of Section 4.3 of the Kinex US License as follow: 
 4.2 Royalties. 

(a) During each Calendar Quarter during the Agreement Term, Kinex shall pay to Hanmi a royalty on annual (Calendar Year) aggregate Net Sales
of Licensed Product by Kinex or its Affiliates based upon the following tiered royalty rates (annual Net Sales is the aggregated total of all sales in the Territory): 
  

	 	(i)	For the amount of such annual Net Sales US < $***M                     ***% 

 

	 	(ii)	For the amount of such annual Net Sales >US$***M                     ***% 

For example, if the annual Net Sales for a given year is US $70M, then Kinex shall pay a royalty of ***% on the first US $***M and ***% on the remaining US
$***M. 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 (b) The tiered royalty rates set forth above shall be (i) reduced by *** percent
(***%)for a Licensed Product if Generic Competition exists in the Territory and (ii) terminated for a Licensed Product for which Substantial Generic Competition exists in the Territory; provided, however, that if Substantial Level
Generic Competition exists for all Licensed Products in the Territory, then the Royalty Term and Agreement Term shall terminate and no further royalties shall be payable by Kinex to Hanmi in the Territory. 

(c) During each Calendar Quarter during the Agreement Term, Kinex shall pay to Hanmi a royalty on annual (Calendar Year) aggregate Net Sales
of all Licensed Products by all sublicensees equal to the lesser of (i) *** Percent (***%) of all royalties payable by the sublicensees to Kinex based on Net Sales of the sublicensee as provided for in the applicable sublicense agreement or
(ii) the amount payable if such royalty is calculated under Section 4.2(a) based on the Net Sales of the sublicensee. 
 ARTICLE
3 
 APPLICATION OF CHINA LICENSE 

3.1 Except as otherwise specifically stated in this Amendment Agreement, all of the terms and conditions of the China License shall remain in full force and
effect and continue to apply, mutatis mutandis, to this Amendment Agreement. 
 3.2 This Amendment Agreement shall continue in force and effect as
long as the China License remains in force and effect. 
 3.3 For further clarity, the Parties agree that this Amendment Agreement constitutes a valid
written amendment to the China License, pursuant to Section 10.8 thereof. 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above. 

 

			
	KINEX PHARMACEUTICALS, INC
		
	By:	 	  

	Name:	 	Johnson YN Lau
	Title:	 	Chief Executive Officer
	
	HANMI PHARMACEUTICAL CO., LTD.
		
	By:	 	  

	Name:	 	Gwan Sun Lee
	Title:	 	President and CEO

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.EX-10.9

 Exhibit 10.9 

EXECUTION COPY 
 FOIA CONFIDENTIAL
TREATMENT REQUESTED 
 Confidential Materials omitted and filed separate with the Securities and Exchange Commission 

Triple asterisks denote omissions 

LICENSE AGREEMENT 
 by and
between 
 KINEX PHARMACEUTICALS, LLC 

and 
 HANMI PHARMACEUTICAL LTD.

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

Confidential Materials omitted and filed separate with the Securities and Exchange Commission 

Triple asterisks denote omissions 

TABLE OF CONTENTS 
  

					
	 	  	Page	 
	 Article 1 DEFINITIONS
	  	 	2	  
		
	 Article 2 GRANT OF RIGHTS
	  	 	15	  
		
	 Article 3 INFORMATION TRANSFER; DEVELOPMENT AND COMMERCIALIZATION; REGULATORY MATTERS
	  	 	16	  
		
	 Article 4 PAYMENTS AND STATEMENTS
	  	 	27	  
		
	 Article 5 REPRESENTATIONS AND WARRANTIES
	  	 	33	  
		
	 Article 6 PATENT MATTERS
	  	 	36	  
		
	 Article 7 CONFIDENTIALITY AND PUBLICITY
	  	 	45	  
		
	 Article 8 TERM AND TERMINATION
	  	 	48	  
		
	 Article 9 INDEMNIFICATION AND INSURANCE
	  	 	54	  
		
	 Article 10 MISCELLANEOUS
	  	 	59	  

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as
of      April, 2011 (“Effective Date”), by and between KINEX PHARMACEUTICALS, LLC, a limited liability company organized and existing under the laws of the State of New York and having its principal
office at 701 Ellicott Street, Buffalo, New York 14203, United States (“Kinex”) and HANMI PHARMACEUTICAL LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 45 Hanmi Tower
BangYee-Dong SongPa-Gu, Seoul, 138-724 South Korea (“Hanmi”). 

WITNESSETH: 

WHEREAS, Kinex owns or Controls the Kinex Intellectual Property of KX01 (also known as KX2-391) and is developing the Compound for
oncological indications; 
 WHEREAS, Hanmi and its Affiliates have experience in the development, marketing, promotion and
sale of pharmaceutical products predominately in Asia and Hanmi desires to obtain the exclusive right and license in the Territory to further develop and thereafter commercialize a Licensed Product for oncology indications in the Field; and

 WHEREAS, Kinex desires to grant to Hanmi such exclusive right and license in the Territory, all on the terms and conditions
set forth below. 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 NOW, THEREFORE, in consideration of the mutual representations, warranties and
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the
respective meanings set forth below: 
 1.1 “Act” means the United States Food, Drug, and Cosmetic Act of 1938, as amended,
and the rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. 
 1.2
“Affiliate” means with respect to a Party: (a) any corporation or business entity of which more than fifty percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general
partnership interest are owned, controlled or held, directly or indirectly, by a Party; (b) any corporation or business entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership
interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of a Party; (c) any corporation or business entity of which, directly or indirectly, an entity
described in the immediately preceding subsection (b) controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock
or general partnership interest of such corporation or entity; or (d) any corporation or business entity of which a Party has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership
interests representing the equity, voting stock or general partnership interest thereof 
 1.3 “Agreement Term” has the
meaning set forth in Section 8.1(a). 

  
 2 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.4 “Breaching Party” has the meaning set forth in Section 8.2(b). 

1.5 “Business Day” means any calendar day, except that if an activity to be performed or an event to occur falls on a,
Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may occur on the next day that is not a
Saturday, Sunday or nationally recognized holiday. 
 1.6 “Calendar Quarter” means for each Calendar Year, each of the
three (3) month periods ending on March 31, June 30, September 30 and December 31; provided, however, that (i) the first Calendar Quarter of any period specified under this Agreement shall extend from the
commencement of such period to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 

1.7 “Calendar Year” means, for the first Calendar Year, the period commencing on the Effective Date and ending on
December 31, 2011, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 

1.8 “C.F.R.” means the United States Code of Federal Regulations. 

1.9 “cGMP” means current Good Manufacturing Practice. 

1.10 “Claims” has the meaning set forth in Section 9.2. 

1.11 “Clinical Studies” means any clinical studies of a Licensed Product conducted on humans. 

  
 3 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.12 “Commercialize” or “Commercialization” means
promotion, marketing, sale, supply, manufacture, import, export and distribution of Licensed Products, including any educational or pre-launch activities. 

1.13 “Commercially Reasonable Efforts” means exerting such efforts and employing such resources as would normally be exerted
or employed by a Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential, and for this Agreement with respect to Regulatory Approval and First Commercial Sale, filing an
application for Regulatory Approval in all countries in the Territory within thirty six (36) months of the first Regulatory Approval in the Territory and achieving First Commercial Sale of the Licensed Product in each country in the Territory
within six (6) months from the date the Regulatory Approval is obtained and the price for the Licensed Product is obtained in accordance with regulatory requirement in such country in the Territory; provided, however, Kinex shall
grant an extension on the foregoing timelines at the reasonable request of Hanmi. 
 1.14 “Completion” means, with respect
to any clinical study, the completion of treatment for the necessary number of patients required by the applicable protocol and completion of the statistical analysis of the study data. 

1.15 “Compound” means the Src/tubulin inhibitor, KX-01 (also known as KX2-391), as diagrammed on Schedule 1.1
attached hereto, and any pharmaceutically acceptable salts, hydrates, solvates, amides, prodrugs and esters of the foregoing, or mixtures thereof. 

  
 4 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.16 “Control” means possession of the ability to grant the rights and
licenses as provided for herein without violating the terms of any agreement or arrangement with any Third Party. 
 1.17
“Copyright” means the rights granted to an author or creator of an original work fixed in any tangible medium of expression, including without limitation, books, literary works, computer programs, and pictorial, graphic, dramatic
and sculptured works, as well as derivative works and translations. 
 1.18 “Data” means any and all research data,
pharmacology data, preclinical data, clinical data, chemistry, manufacturing and control (“CMC”) data and/or all other similar documentation generated in connection with the Compound or Licensed Product. 

1.19 “Develop” or “Development” means those activities undertaken with respect to the Compound or Licensed
Product which are devoted to the progression of a potential pharmaceutical product in Clinical Studies and any other activities directed toward quality issues, publication, Regulatory Approval, formulation, production or CMC of such Compound or
Licensed Product, including any other pre-launch activities. 
 1.20 “Disputed Claim” has the meaning set forth in
Section 9.4(b). 
 1.21 “Dollar” or “$” means the lawful currency of the United States. 

1.22 “Drug Approval Application” means an application for Regulatory Approval of a Licensed Product as a pharmaceutical
product in a country in the Territory. 
 1.23 “Effective Date” has the meaning set forth in the Preamble hereof. 

  
 5 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.24 “Field” means the prevention or treatment of oncology disease or
condition in humans. 
 1.25 “First Commercial Sale” means, with respect to any Licensed Product, the first sale to a Third
Party for end use or consumption of such Licensed Product in a country in the Territory by Hanmi, its Affiliates or sublicensees after receipt of Regulatory Approval in such country or, where Regulatory Approval is not required, then the first sale
for end use or consumption of a Licensed Product to a Third Party in that country in the Territory in connection with the nationwide introduction of such Licensed Product in that country in the Territory by Hanmi, its Affiliates or sublicensees.

 1.26 “IFRS” means International Financial Reporting Standards as adopted by the International Accounting Standard Board,
consistently applied. 
 1.27 “Generic Competition” shall be deemed to exist in a particular country as of any date if,
during the two (2) immediately preceding Calendar Years, (a) Generic Products have a market share in the applicable country of at least *** percent (***%) of the then combined unit volume of Licensed Product and Generic Products, or
(b) Net Sales by Hanmi in the applicable country decrease by at least *** percent (**%) with each of (a) and (b) measured as an average taken over such two (2) Calendar Years as compared to the Calendar Year of Peak Sales.

 1.28 “Generic Product” means any product containing the Compound as an active pharmaceutical ingredient sold by a Third
Party (excluding, for these purposes, an Affiliate or sublicensees of Hanmi). 
 1.29 “Hanmi Indemnified Parties” has the
meaning set forth in Section 9.1. 

  
 6 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.30 “Hanmi Know-How” means all Know-How that are owned or Controlled by
Hanmi as of the Effective Date and during the Agreement Term. 
 1.31 “Hanmi Patent Rights” means all Patent Rights that
are owned or Controlled by Hanmi as of the Effective Date and during the Agreement Term. 
 1.32 “Improvements” means all
inventions and Know-How, patentable or otherwise, made, created, developed, conceived or reduced to practice by or on behalf of a Party and/or any of its Affiliates pursuant to activities relating to or contemplated by this Agreement during the
Agreement Term, that have application or relate to the Compound or Licensed Product for use in the Field including developments in the manufacture, formulation, ingredients, preparation, presentation, means of delivery or administration, dosage,
indication, methods of use or packaging and/or sale of the Compound or Licensed Product. 
 1.33 “IND” means an
Investigational New Drug application, this carries the same meaning in each of the countries in the Territory similar to what is described in the United States in 21 C.F.R. Section 312.23, obtained for purposes of conducting clinical trials in
accordance with the requirements of the Act and the regulations promulgated thereunder, including all supplements and amendments thereto relating to the use of Compound or Licensed Product in the Field. 

1.34 “Initiation” means when an IND is submitted for Clinical Studies to the Regulatory Authority of the applicable country.

 1.35 “Insurance” has the meaning set forth in Section 9.6(a). 

  
 7 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.36 “Intellectual Property” means Patent Rights, Know-How, Copyrights, and
Trademarks collectively, including applications thereof, relating to the Compound or Licensed Product, as well as any Improvements thereto. 

1.37 “Kinex Indemnified Parties” has the meaning set forth in Section 9.1. 

1.38 “Kinex Intellectual Property” means the Kinex Patent Rights, Kinex Know-How and Intellectual Property owned or
Controlled by Kinex or any of its Affiliates listed in Schedule 1.2. 
 1.39 “Kinex Know-How” means all
Know-How that are owned or Controlled by Kinex or any of its Affiliates. 
 1.40 “Kinex Patent Rights” means all Patent
Rights that are owned or Controlled by Kinex or any of its Affiliates, including the Patent Rights. 
 1.41 “Know-How”
means all proprietary information and technology, including trade secret information, developments, discoveries, methods, techniques, formulations, Data, and other information, whether or not patentable, that relate to the Compound or Licensed
Product, or any Improvement. 
 1.42 “Law(s)” means all laws, statutes, rules, regulations, ordinances and other
pronouncements having the binding effect of law of any governmental authority. 
 1.43 “Licensed Products” means any
pharmaceutical preparation in final form (or, where the context so indicates, the form under development) containing the Compound KX01 as an active pharmaceutical ingredient for use in the Field in the Territory. 

  
 8 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.44 “Losses” means any and all damages, awards, deficiencies, settlement
amounts, defaults, assessments, fines, dues, penalties (including penalties imposed by any governmental authority), costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including court costs, interest and
reasonable fees of attorneys, accountants and other experts) awarded or otherwise paid or payable to Third Parties. 
 1.45
“NDA” means a New Drug Application in any of the countries in the Territory similar to the NDA submitted to the FDA to obtain approval for the marketing of a Licensed Product in the United States, together with all subsequent
submissions, supplements and amendments thereto. 
 1.46 “Net Sales” means the gross sales amount of Licensed Products
invoiced to Third Parties by Hanmi, its Affiliates and sublicensees, less the following deductions (to the extent included in such gross sales amount): 

(a) quantity and/or cash discounts therefor; 

(b) customs, duties, sales and similar taxes; 

(c) amounts allowed or credited by reason of rejections, return of goods (including as a result of recalls, market withdrawals
and other corrective actions), and retroactive price reductions or allowances specifically identifiable as relating to a Licensed Product including allowances and credits related to inventory management or similar agreements with wholesalers; 

  
 9 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (d) amounts incurred resulting from government (or any agency thereof)
mandated rebate programs in the Territory; 
 (e) Third Party rebates, patient discount programs, administrative fees and
chargebacks or similar price concessions related to the sale of a Licensed Product; 
 (f) bad debt recognized by Hanmi for
accounting purposes as not collectible; 
 (g) the expenses for insurance, freight, packing, shipping and transportation;

 (h) sample costs incurred during the pre-marketing activities; 

(i) commissions paid to agents or distributors to secure tender offers or other purchases by local authorities; and 

(j) as agreed by the Parties, such agreement not to be unreasonably withheld, any other specifically identifiable amounts
included in a Licensed Product’s gross sales amount that were or ultimately will be credited and that are similar to those listed above, all in accordance with IFRS. 

All such discounts, allowances, credits, rebates and other deductions shall be fairly and equitably allocated to the Licensed Product, and, to
the extent applicable, other products or services of Hanmi or its Affiliates such that the Licensed Products do not bear a disproportionate portion of such deductions. For the avoidance of doubt, Net Sales shall not include sales by Hanmi to its
Affiliates or sublicensees for resale; provided that, if Hanmi sells a Licensed Product to an Affiliate or sublicensee for resale, then the Net Sales calculation shall include the amounts invoiced by such Affiliate or sublicensee to

  
 10 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
Third Parties on the resale of a Licensed Product. For purposes of this Agreement, “sale” shall not include transfers or other distributions or dispositions of a Licensed Product, at no
charge, for regulatory purposes, clinical trials, samples, free products or in connection with patient assistance programs or other charitable purposes or to physicians or hospitals for promotional purposes. A Licensed Product shall be considered
“sold” only when billed or invoiced. 
 1.47 “Ongoing Clinical Study” means Clinical Studies with enrolled
patients that are in the process of being conducted. For the avoidance of doubt, this does not include Clinical Studies where no patient dosing has occurred regardless of enrollment of patients. 

1.48 “Party” means Kinex or Hanmi, as the context may require. 

1.49 “Parties’ Patent Rights” has the meaning set forth in Section 6.3(a). 

1.50 “Patent Rights” means any patents, patent applications, certificates of invention, or applications for certificates of
invention and any supplemental protection certificates, together with any extensions, registrations, confirmations, reissues, substitutions, divisions, continuations or continuations-in-part, reexaminations or renewals thereof that relate to the
Compound, Licensed Product or any Improvement, including methods of development, manufacture, formulation, preparation, presentation, means of delivery or administration, dosage, packaging, sale or use relating to the Compound or Licensed Product.

 1.51 “Peak Sales” means the highest Net Sales of the Licensed Product achieved during any Calendar Year following the
First Commercial Sale of the License Product within each applicable country within the Territory. 

  
 11 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.52 “Phase I Clinical Study(ies)” means the initial introduction of an
investigational new drug into humans primarily designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness, and
may also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. 

1.53 “Phase II Clinical Study(ies)” means the Clinical Study related to the product, in particular, the study that will show
the efficacy of the product and also provide guidance to the effective dose regimen required. In general, this type of study will determine the effective dose regimen for the clinical indication. Safety data is also collected in this type of study.
For this Agreement, it is contemplated that multiple Phase II Clinical Studies in the oncology area will be performed to prove the efficacy of KX01 and also to determine the effective dose for Phase III Clinical Study(ies). 

1.54 “Phase III Clinical Study(ies)” means the Clinical Study related to the product, in particular, the study that is a
registration study designed to demonstrate statistically (p-value of less than 0.05 or <0.025 for split-alpha study design) the efficacy of the drug for specific indications. This type of study is usually conducted after agreement with the
regulatory authority that a positive result from such a study conducted under good clinical practice will be enough for the regulatory authority to provide marketing approval of the product. 

  
 12 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.55 “Prime Rate” means the rate announced from time to time by HSBC Bank,
N.A. as its “prime rate” in New York, New York, USA which is the base rate upon which other rates charged at such bank are based, and is the best rate available to premium customers at such bank. 

1.56 “Product Label(ing)” shall have the same meaning as defined in the Act and as interpreted by the Regulatory Authority in
each country in the Territory. 
 1.57 “Proprietary Information” means any and all scientific, clinical, technological,
regulatory, marketing, financial and commercial information or data, whether communicated in writing, orally or by any other means, which is owned and under the protection of one Party and is provided by that Party to the other Party in connection
with this Agreement, and shall include Kinex Know-How and Hanmi Know-How, as applicable. 
 1.58 “Regulatory Approval”
means approval by the relevant Regulatory Authority of an NDA or other Drug Approval Application, health registration, common technical document, regulatory submission, notice of compliance and any other license or permit required to be approved for
the supply, manufacture, use, storage, distribution, import, export, transport, promotion, marketing and sale of a Licensed Product in a country, region or other regulatory jurisdiction. 

1.59 “Regulatory Authority” means any governmental authority in a country, region or other regulatory jurisdiction that
regulates the supply, manufacture, use, storage, distribution, import, export, transport, promotion, marketing and sale of a Licensed Product. 

1.60 “SEC” means the United States Securities and Exchange Commission and any successor agency having substantially the same
functions. 

  
 13 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 1.61 “Substantial Level Generic Competition” shall be deemed to exist in a
particular country as of any date if, during the two (2) immediately preceding Calendar Years, (a) Generic Products have a market share in the applicable country of at least *** percent (***%) of the then combined unit volume of Licensed
Product and Generic Products, or (b) Net Sales by Hanmi in the applicable country decrease by at least *** percent (***%) with each of (a) and (b) measured as an average taken over such two (2) Calendar Years as compared to
the Calendar Year of Peak Sales. 
 1.62 “Territory” means the following designated countries only: South Korea, Greater
China (including Mainland China, Taiwan and Hong Kong), Singapore, Malaysia, Thailand, Philippines, Indonesia, and Vietnam. All other countries are expressly excluded including, but not limited to, the Asian countries of Japan, India, Australia and
New Zealand. 
 1.63 “Third Party(ies)” means a person or entity who or which is neither a Party nor an Affiliate of a
Party. 
 1.64 “Trademark” means all trademark(s) for which either Party has sought registration and all related service
marks, domain names and other trademark related rights relating to the Licensed Product. 
 1.65 “Valid Claim” means any
claim in an active patent application or issued in an unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction following exhaustion of all
possible appeal processes, and which has not been admitted to be invalid or unenforceable through reissue, reexamination or disclaimer and has not been terminated for failure to pay maintenance fees. 

  
 14 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 ARTICLE 2 

GRANT OF RIGHTS 
 2.1
Grants by Kinex. Subject to the terms and conditions of this Agreement, Kinex hereby grants to Hanmi an exclusive right and license throughout the Territory as defined (including the right to grant sublicenses to Third Parties located within
the Territory with prior written notice to Kinex) to practice under the Kinex Intellectual Property in order to develop, label, package, import, export, promote, distribute, make, use, sell, offer for sale, register, commercialize and otherwise
exploit the Compound and Licensed Product(s) containing the Compound in the Field; provided, however, that, notwithstanding the exclusive rights granted to Hanmi hereunder, Kinex shall retain the right to use the Kinex Intellectual
Property in the Territory solely as necessary to perform its obligations under this Agreement. Any Affiliates of Hanmi exercising any rights of Hanmi under this Agreement shall be located within the Territory. With respect to sales to Third Party
distributors or other parties purchasing Licensed Product for resale, Hanmi shall use reasonable efforts to restrict such resales to within the Territory. 

2.2 Retained Rights; No Implied Licenses. All rights not specifically granted to Hanmi under this Agreement are reserved and retained
by Kinex. Nothing in this Agreement shall be deemed to constitute the grant of any license or other right to Hanmi, to or in respect of any product, patent, trademark, Proprietary Information, trade secret or other data or any other intellectual
property of the other Party, except as set forth under this Agreement (including, but 

  
 15 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
not limited to, the Mimetica and Opal discovery platforms or any compound or molecule in the Kinex libraries other than KX01). Kinex retains the right to manufacture Compound or Licensed Product
within the Territory for sales outside the Territory. For the avoidance of doubt, Kinex shall not market, distribute, sell and import the Licensed Products within the Territory. 

2.3 Right of First Refusal. Kinex hereby grants a right of first refusal to Hanmi for any KX01 related formulation or pharmaceutically
acceptable salt, prodrug, metabolite, or combination drug (collectively “RoFR Product”) for which Kinex intends to grant an exclusive right and license within the Territory. Kinex shall provide Hanmi with written notice of the terms
on which Kinex proposes to license such RoFR Product within the Territory, the terms of which must be in accordance with standard business practices, and Hanmi shall have ninety (90) days from the date of receipt of such written notice to
send a written reply to Kinex indicating its desire to license such RoFR Product on the terms contained in Kinex’s written notice. If Hanmi does not respond within the ninety (90) days, Kinex shall be free to license such RoFR Product to
third parties in the Territory on the terms and conditions contained in the written notice sent to Hanmi. Any such RoFR Product that is subsequently marketed or sold by Kinex or a Third Party in the Territory shall not constitute a Generic Product
under this Agreement. 
 ARTICLE 3 

INFORMATION TRANSFER; DEVELOPMENT AND COMMERCIALIZATION; 

REGULATORY MATTERS 
 3.1
Information and Transfer of Kinex Intellectual Property. As soon as practicable, but in no event later than thirty (30) days after the Effective Date, Kinex shall disclose and 

  
 16 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
deliver to Hanmi electronic copies (or, upon Hanmi’s request, copy of the originals) of all Data for continued Development and Commercialization in the Territory. In addition to the
foregoing, Kinex shall provide Hanmi with such assistance as Hanmi may reasonably request (at Hanmi’s cost and expenses) in connection with the foregoing disclosures, including making available at their place of employment (or such other
location as the Parties may mutually agree upon) the assistance of such persons that were involved with the Clinical Studies and the Kinex Intellectual Property. The Party requesting copies of Data shall reimburse the other Party for the cost of
providing copies of such Data. 
 3.2 Regulatory Filings and Applications in the Territory. Upon completion, and upon Hanmi’s
request, Kinex shall provide to Hanmi a copy of a Chinese translation of Kinex’s IND application as filed with the United States Regulatory Authority, and Hanmi shall reimburse Kinex for the cost of such translation. 

3.3 Development and Commercialization. 

(a) General. Hanmi shall be responsible for and shall itself, or through its Affiliates or sublicensees, conduct
Development and Commercialization in the Territory during the Agreement Term as described by this agreement. Within ninety (90) days after the Effective Date, Hanmi shall prepare a draft Development plan consistent with regional development
requirement and a budget in English with respect to the Development and Commercialization for countries within the Territory to be submitted to the Development and Commercialization Steering Committee (as defined in Section 3.5) which will
agree on and oversee the plan for Development and Commercialization during the Agreement Term. If (i) Hanmi fails to obtain Regulatory Approval in any country in 

  
 17 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
the Territory within thirty six (36) months of the first Regulatory Approval in any country in the Territory (the first Regulatory Approval shall only mean the approval achieved through the
regular path in any countries the Territory, excluding the fast-track approval which is permitted exceptionally in certain countries within the Territory.) or (ii) Hanmi fails to commercialize the Licensed Product and achieve First Commercial
Sale in any one or more of the countries in the Territory within six (6) months from the date the Regulatory Approval is obtained and the price for the Licensed Product is obtained in accordance with regulatory requirement in such country in
the Territory, in both cases subject to an extension, on the foregoing timelines, of either (x) twenty four (24) months at the reasonable request of Hanmi, or (y) any other reasonable period of time (not to exceed twenty four
(24) months) sufficient enough to allow Hanmi to supplement its application for Regulatory Approval with additional materials and information as may be necessary or advisable by Hanmi, Kinex shall have the option, if it elects to do so, to
terminate all rights and licenses under this Agreement with respect to such country upon the end of such extension. 
 (b)
Summary Reports. Upon Kinex’s sixty (60) day prior written request, made within thirty (30) days after the end of the first Calendar Year following the Effective Date and each year thereafter during the Agreement Term, if
timely requested, Hanmi shall provide Kinex with a written summary of Development and Commercialization undertaken on a country by country basis during the then current Calendar Year consistent with written reports issued by Hanmi in the ordinary
course of its business, which form is specified on Schedule 1.3. 

  
 18 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (c) Clinical Studies. Unless stated otherwise, Hanmi will be
responsible for conducting and administering at its sole cost and expense, all the Clinical Studies required for Regulatory Approval in each of the countries within the Territory as follows: 

(i) Conduct all Clinical Studies including IND enabling studies that are required to initiate Phase II Study(ies) and at least
two Phase II Studies in each of the countries within the Territory identified in the Development plan. The aggregate number for such studies is at least one hundred twenty (120) patients with recruitment completed within thirty-six
(36) months of the date of clinical Development plan. 
 (ii) Participate in the global Phase III Studies in such a
manner in conjunction with Kinex that will support the registration of the Compound in each of the countries within the Territory requiring Clinical Studies as identified in the Development plan (with initiation of a Phase III Study in the relevant
countries in the Territory within twelve (12) months after the successful Completion of a Phase II Study in the relevant countries in the Territory and the number of patients participating under the Phase III Study(ies) in the Territory and the
scope of the global Phase III Studies must be discussed and agreed by both Parties prior to Initiation of such Phase III Study(ies)). 

(iii) The Data and results of any Clinical Studies conducted by a Party or its ex-Territory partners shall be made available to
the other Party for referencing at no cost to the requesting Party for regulatory filing purposes. 
 If Hanmi fails to comply with the
timelines set forth above, Kinex shall grant a one (1) time extension of six (6) to twelve (12) months on the foregoing timelines at the 

  
 19 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
reasonable request of Hanmi. In the event that Hanmi fails to comply with such timelines despite an extension, Kinex shall conduct good faith discussions with Hanmi regarding the timelines, and
if such matter is unable to be resolved, Kinex, may, with prior written notice to Hanmi, terminate all rights and licenses under this Agreement. 

(d) Payment of Development and Commercialization Costs. Hanmi shall be responsible for all costs associated with
Development and Commercialization in the Territory. Notwithstanding the generality of the foregoing, Hanmi shall reimburse Kinex for the direct and actual costs incurred by Kinex in carrying out any Development within the Territory that was
authorized or approved in writing in advance by Hanmi, subject to a full accounting of such direct costs. Provided, however, any costs incurred in connection with pre-clinical development that were not foreseeable as of the Execution
Date shall be borned by Kinex; provided, however, that if such pre-clinical development shall be required specifically for the regulatory approval in any countries within the Territory, such costs incurred in connection with
pre-clinical development shall be divided among the Parties upon mutual discussions of the Parties. 
 (e) Records.
Under this Agreement, Hanmi shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in accordance with good industry practice, which shall be complete and accurate in all material
respects and shall fully and properly reflect all work done and results achieved, including all Know-How and including individual case report forms, in the form required by applicable Laws. Kinex shall have the right, upon at least
sixty (60) days prior written notice to Hanmi and no more than once in any Calendar Year, to inspect and audit such records. Kinex shall reimburse Hanmi for any costs incurred by Hanmi with respect to any such inspection and audit by
Kinex. 

  
 20 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (f) Promotional Materials and Activities. Hanmi shall create and
develop the advertising and promotional materials for the Licensed Products in the Territory with the written approval of Kinex (which shall not be unreasonably withheld) with respect to all such materials. As holder of the Regulatory Approvals in
the Territory, Hanmi shall be responsible for all submissions and interactions with the Regulatory Authorities regarding approval of all Licensed Product-related promotional materials that require Regulatory Approval. 

(g) Ownership of Copyrights and Trademarks. Kinex retains all rights to establish a global brand for each Licensed
Product and shall own all Copyrights and Trademarks for the Licensed Product in the Territory with respect to such global branding strategy. Hanmi shall have the right, with good cause, to establish a brand for a Licensed Product in any country in
the Territory that is distinct from Kinex’s global branding, and Hanmi shall own all such distinct Copyrights and Trademarks. Each Party shall be responsible for searching, clearing and filing applications for registration of its own
Copyrights, Trademarks and trade dress at its own cost and responsibility. Kinex shall execute all documents and take all actions as are requested by Hanmi with respect to such filings and registrations. Kinex shall have the right to use the Hanmi
Trademarks and Copyrights with respect to the Compound and Licensed Product upon Hanmi’s prior written consent. 

  
 21 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (h) Sales of Licensed Product. All sales of Licensed Products shall be
made, recorded, invoiced and collected by Hanmi. All terms regarding Licensed Product sales, including terms with respect to credit, pricing, cash discounts, rebates, chargebacks, bad debt write-offs, and other fees and charges, and returns and
allowances shall be set solely by Hanmi. 
 (i) Supply of Licensed Product. During the Agreement Term, Kinex shall
supply, or cause to be supplied, in accordance with regulatory requirements and as requested by Hanmi, the requirements for Licensed Product for Clinical Studies and Regulatory Approval in the Territory as reasonably practical to Hanmi at a purchase
price payable by Hanmi equal to Kinex’s cost for the Licensed Product. For the avoidance of doubt, Hanmi shall be responsible for any customs duties. After Hanmi elects to manufacture its own investigational products containing the Compound,
Kinex shall have the right to purchase such investigational products from Hanmi for Clinical Studies and Regulatory Approval outside the Territory at a purchase price payable by Kinex equal to Hanmi’s cost for the investigational products. 

3.4 Regulatory Matters. 

(a) Responsibility of Hanmi. 

From and after the Effective Date: 

(i) Hanmi shall have sole authority and responsibility for the timely preparation, filing and prosecution of all filings,
submissions, authorizations or approvals with Regulatory Authorities, and shall own and control all such filings, submissions, 

  
 22 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
authorizations and approvals, including any IND, NDA or other Drug Approval Application in the Territory. Hanmi shall provide copies of all such filings, submissions, authorizations and approvals
upon reasonable request from Kinex, at Kinex’s sole cost and expense. 
 (ii) Hanmi shall be the primary contact with
each Regulatory Authority in the Territory and shall be solely responsible for all communications with each Regulatory Authority that relate to any IND, NDA, or other Drug Approval Application in the Territory, provided, however, that
upon the reasonable request of Hanmi, Kinex shall provide appropriate personnel to participate in discussions with a Regulatory Authority regarding the regulatory review process and shall assist and consult with Hanmi in applying for Regulatory
Approval at Hanmi’s cost and expense. 
 (iii) From and after receipt of each Regulatory Approval, Hanmi shall have
exclusive authority and responsibility to submit all reports or amendments necessary to maintain Regulatory Approvals and to seek revisions of the conditions of each such Regulatory Approval in the Territory and shall keep Kinex informed of any such
actions. Hanmi shall have sole authority and responsibility to seek and/or obtain any necessary approvals for any Product Label, or prescribing information, package inserts, monographs and packaging used in connection with a Licensed Product, in
addition to promotional materials used in connection with a Licensed Product in the Territory. Hanmi shall determine whether the foregoing items require Regulatory Approval in the Territory. 

  
 23 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (b) Responsibility of Kinex. 

(i) Kinex shall fully cooperate and assist Hanmi, upon Hanmi’s request, with respect to Hanmi’s performance of its
obligations under this Agreement. Kinex shall not be required, however to incur any Third Party costs to meet its obligation to cooperate and assist Hanmi under this Section. If Kinex’s cooperation and assistance will be limited due to Third
Party costs, Kinex shall provide Hanmi an estimate, including supporting documentation, of such Third Party costs. Unless otherwise agreed herein, or with the prior agreement of Hanmi otherwise, Hanmi shall not be responsible for any payment to
Kinex in consideration of any cooperation or assistance rendered by Kinex. 
 (ii) Regulatory Cooperation. Each Party
is responsible for matters concerning adverse drug reactions, safety information and compliance with regulatory requirements. Each Party shall, upon the request of the other Party, provide any such data in each Party’s actual possession to the
other Party that is required by the United States Regulatory Authority. The Parties hereby agree that they will each make their best Commercially Reasonable Efforts in coordinating their respective regulatory, Development and Commercialization
efforts under this Agreement. 
 3.5 Appointment and Administration of Development and Commercialization Steering Committee for the
Territory. 
 (a) As soon as practicable after the execution of this Agreement and in no event later than thirty
(30) days after the Effective Date, the Parties will establish a four (4) person steering committee to oversee and review the Development and Commercialization of the Licensed Products in the Territory, which will include
two (2) representatives of each of Hanmi and Kinex (the “Development and  

  
 24 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
Commercialization Steering Committee”) and will be chaired by one of the representatives of Hanmi. All actions, decisions and approvals of the Development and Commercialization
Steering Committee shall be determined upon an affirmative majority vote of its members. 
 (b) One (1) member appointed
by each Party will be a senior officer of such Party who is either (i) responsible for product development or (ii) has substantial experience in product development for similar products who is acceptable to the other Party. Each Party, at
its sole discretion, may at any time during the Term of this Agreement replace either of its appointed members with prior written notice to the other Party. Each Party will use commercially reasonable efforts to cause its respective representatives
to attend all meetings of the Development and Commercialization Steering Committee. Each Party will bear its respective travel and out-of-pocket expenses incurred by its members or representatives in connection with the Development and
Commercialization Steering Committee’s meetings. 
 (c) The Development and Commercialization Steering Committee will
meet at least once every Calendar Quarter or more or less frequently as the Parties mutually deem appropriate, at a time and place agreed by the Parties. The Development and Commercialization Steering Committee may also convene, vote or hold
discussions from time to time through other methods of communication, as deemed necessary or appropriate by the Parties, including without limitation, telephone, video conference or email. 

  
 25 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (d) In the event there is a disagreement among the members of the Development
and Commercialization Steering Committee, the members of the Development and Commercialization Steering Committee shall promptly present such issue in dispute to the relevant executive at Hanmi and Kinex who has the principal responsibility for the
work under this Agreement. Once informed, the executives shall meet to discuss each party’s view and to clarify the basis for such disagreement. If such executives are unable to resolve such dispute within thirty (30) days of such meeting,
(i) such dispute shall be submitted to arbitration if it is within the framework of this Agreement, or (b) Hanmi’s decision shall be final and binding if such dispute is not within the framework of this Agreement and is applicable to
issues only within the Territory. The arbitration shall be conducted in Singapore in accordance with the Singapore International Arbitration Centre Rules. If a disagreement or dispute under this Section results in a delay in Hanmi’s ability to
meet any timeline provided for in this Agreement, such timeline shall be extended for a period of time equal to the length of such delay. 

(e) The Development Steering and Commercialization Committee shall be responsible for (i) approval and amendment, from
time to time, of the plan for Development and Commercialization, (ii) the protocols for Clinical Trials of Licensed Product, (iii) approval of all contracts relating to the Development of Licensed Product, (iv) the formulation used in
respect of Licensed Product, and (v) contracts relating to the Commercialization of Licensed Product. 

  
 26 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 ARTICLE 4 

PAYMENTS AND STATEMENTS 

4.1 Milestone Fees. In consideration of the rights granted by Kinex hereunder, Hanmi shall pay Kinex the following milestone fees,
contingent upon occurrence of the specified event, with each milestone fee to be paid no more than once with respect to the achievement of such milestone event (but payable the first time such milestone event is achieved): 

 

					
	(a)	  	Effective Date	  	US $1.5M
			
	(b)	  	Completion anywhere in the Territory of one Phase II Study that meets the criteria set forth in the applicable protocol	  	US $***
			
	(c)	  	Completion anywhere in the Territory of one Phase III Study for the first indication in oncology that meets the criteria set forth in the applicable protocol	  	US $***
			
	(d)	  	First Regulatory Approval in any one country in the Territory	  	US $***

 Each milestone fee shall be deemed earned as of the achievement of the related milestone event and shall be paid by Hanmi
within thirty (30) Business Days after receipt of written notice of the achievement of each milestone event to Kinex. 

  
 27 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 4.2 Royalties. 

(a) During each Calendar Quarter during the Agreement Term, Hanmi shall, pursuant to Section 4.3(a), pay to Kinex a
royalty on annual (Calendar Year) aggregate Net Sales of Licensed Product based upon the following tiered royalty rates (annual Net Sales is the aggregated total of all sales in the Territory): 

(i) For the amount of such annual Net Sales < US
$***M                     ***% 

(ii) For the amount of such annual Net Sales > US
$***M                    ***% 
 For
example, if the annual Net Sales for a given year is US $70M, then Hanmi shall pay a royalty of ***% on the first US $***M and ***% on the remaining US $***M. 

(b) The tiered royalty rates set forth above shall be reduced by *** percent (***%) in each country in which Generic
Competition exists; provided, however, that if Substantial Level Generic Competition exists in a country, then the Royalty Term and Agreement Term shall terminate with respect to such country, and no further royalties shall be payable
by Hanmi to Kinex in the subject country. 
 4.3 Royalty Reports and Payments. 

(a) Royalty Payments. Within sixty (60) days following the end of each Calendar Quarter during the Royalty Term,
Hanmi shall submit to Kinex an accounting report for such applicable Calendar Quarter for each relevant country within the Territory, which sets forth the gross sales, Net Sales and the royalties payable in accordance with Section 4.2(a) for
such Calendar Quarter, with a breakdown of all deductions taken in any such calculations, in accordance with the definition of “Net 

  
 28 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
Sales”. Any conversion to Dollars shall be calculated in accordance with Section 4.4(c). In the event of any royalty reduction during any Calendar Quarter due to Generic Competition in
any country in the Territory, the report for such Calendar Quarter shall also provide the basis for the determination of such Generic Competition. Royalties shown to have accrued by each report shall be due and payable on the date such report is
due. 
 (b) Hanmi shall also furnish Kinex a written report for each relevant country within the Territory during the first
four (4) Calendar Quarters commencing after the expiration of the Royalty Term stating the basis for Net Sales then being free of royalty obligations hereunder. Hanmi shall thereafter have no further obligation to include in any written reports
the Net Sales of such Licensed Product in such country for purposes of the royalty calculation for any Calendar Quarter. This obligation shall survive the termination or expiration of this Agreement in any such country. 

(c) Each Party shall keep and require its Affiliates to keep complete and accurate records in sufficient detail to permit
accurate determination of all amounts necessary for calculation and verification of all payment obligations set forth in this Article 4 for a period of thirty six (36) months from the end of the relevant Calendar Quarter. 

  
 29 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 4.4 General Payment Provisions. 

(a) Payment Method. All payments under this Agreement shall be made in Dollars by bank wire transfer in immediately
available funds to an account designated by Kinex. 
 (b) Withholding Taxes. Hanmi may deduct the amount of any taxes
imposed on Kinex which are required to be withheld or collected by Hanmi, its Affiliates or sublicensees under the laws, rules or regulations of any country on amounts owing from Hanmi to Kinex hereunder. Any such taxes required to be withheld or
collected shall be an expense of Kinex. To the extent Hanmi, its Affiliates or sublicensees pay such withholding taxes to the appropriate governmental authority on behalf of Kinex, Hanmi shall promptly deliver to Kinex proof of payment of such
taxes. 
 (c) Currency Exchange. For purposes of computing royalties on Net Sales in any country outside the United
States, the Net Sales shall be converted to Dollars using the year-to-date average rate of exchange for Dollars used by Hanmi for its internal financial accounting purposes; provided, however, that if for any reason conversion into
Dollars cannot be made in a country in the Territory, then notwithstanding the provisions of Section 4.4(a), payment may be made in the currency of such country by deposit in the name of Kinex in a bank account designated by it in such country.

 (d) Except as otherwise defined herein, all financial calculations by either Party under this Agreement shall be
calculated in accordance with IFRS. In addition, all calculations shall give pro rata effect to and shall proportionally adjust (by giving effect to the number of applicable days in such Calendar Quarter) (i) for any Calendar Quarter that
is shorter than a standard Calendar Quarter or any Calendar Year that is shorter than 

  
 30 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
four (4) consecutive full Calendar Quarters, or (ii) as a result of a determination, in accordance with the terms of this Agreement, that the first or last day of such Calendar Quarter
(including as a result of termination of this Agreement) shall be deemed other than the actual first or last day of such Calendar Quarter, or that the first or last day of such Calendar Year shall be deemed other than the actual first or last day of
such Calendar Year. 
 4.5 Audits. Upon the written request of Kinex, Hanmi shall permit an independent certified public accounting
firm of recognized standing, selected by Kinex and acceptable by Hanmi (provided that such accounting firm shall not be retained or compensated on a contingency basis and shall have entered into a confidentiality agreement with Kinex
in the form and substance reasonably satisfactory to Hanmi), to have access not more than once in any Calendar Year, during normal business hours, to such of the records of Hanmi as may be reasonably necessary to verify the accuracy of the reports
under Section 4.3 hereof for any year ending not more than twenty four (24) months prior to the date of such request. The accounting firm shall disclose to Kinex whether the reports are correct or incorrect, the specific details concerning
any discrepancies (including the accuracy of the calculation of Net Sales and the resulting effect of such calculations on the amounts payable by Hanmi under this Agreement) and such other information that should properly be contained in a report
required under this Agreement (the “Audit Report”). 
 (a) If such accounting firm concludes that additional
amounts were owed during such year, and Hanmi agrees with such conclusion, then Hanmi shall pay the additional payments, together with interest at the Prime Rate on the amount of such 

  
 31 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
additional payments, within thirty (30) days of the date Kinex delivers the Audit Report to Hanmi. In the event that Hanmi disagrees with the accounting firm’s conclusion, Hanmi shall
not have the obligation to make any additional payments to Kinex until there is a mutual agreement of the Parties regarding the amount owed by Hanmi. For the avoidance of doubt, Hanmi is not obligated to pay any interest for the period during which
the Parties were in dispute of the account firm’s conclusion and amount owed thereunder. In the event such accounting firm concludes that amounts were overpaid by Hanmi during such period, Kinex shall repay Hanmi the amount of such overpayment,
together with interest at the Prime Rate on the amount of such overpayment, within thirty (30) days of the date the auditing Party delivers to the audited Party such accounting firm’s Audit Report. The fees charged by such accounting
firm shall be paid by Kinex, provided, however, that if an error in favor of the Kinex of more than five percent (5%) of the payments due hereunder for the period being reviewed is discovered, then the fees and expenses of the
accounting firm shall be paid by Hanmi. 
 (b) Upon the expiration of twenty four (24) months following the end of any
year for which Hanmi or Kinex has made payment in full of amounts payable with respect to such year, and in the absence of negligence or willful misconduct of Hanmi or Kinex or a contrary finding by an accounting firm pursuant to
Section 4.5(a), such calculation shall be binding and conclusive upon Hanmi or Kinex, and Hanmi or Kinex, as applicable, shall be released from any liability or accountability with respect to royalties or other payments for such year. 

  
 32 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 ARTICLE 5 

REPRESENTATIONS AND WARRANTIES 

5.1 General Representations. Each Party hereby represents and warrants to the other Party as follows: 

(a) Such Party is a corporation or limited liability company duly organized, validly existing and is in good standing under the
laws of the jurisdiction of its incorporation or formation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such
qualification and failure to have such would prevent it from performing its obligations under this Agreement; 
 (b) The
execution, delivery and performance of this Agreement by such Party has been duly authorized by all necessary corporate action and do not and will not (i) violate any provision of any law, rule, regulation, order, writ, judgment, injunction,
decree, determination or award presently in effect having applicability to it or any provision of its charter or bylaws; or (ii) conflict with or constitute a default under any other agreement to which such Party is a party; 

(c) This Agreement has been duly executed and is a legal, valid and binding obligation of such Party, enforceable against it in
accordance with the terms and conditions hereof, except as enforceability may be limited by (i) any applicable bankruptcy, insolvency, reorganization, moratorium or similar law affecting creditor’s rights generally, or (ii) general
principles of equity, whether considered in a proceeding in equity or at law; 

  
 33 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (d) Such Party is not under any obligation to any person or entity,
contractual or otherwise, that is in conflict with the terms of this Agreement, nor shall such Party undertake any such obligation during the Agreement Term; 

(e) Such Party has obtained all authorizations, licenses, permits, consents and approvals, governmental or otherwise, necessary
for the execution and delivery of this Agreement, and to otherwise perform such Party’s obligations under this Agreement; 

(f) Neither Party, nor any of its Affiliates, are a party to, or are otherwise bound by, any oral or written agreement that
will result in any person or entity obtaining any interest in, or that would give to any Third Party any right to assert any claim in or with respect to, any of such Party’s or the other Party’s rights under this Agreement; and 

(g) Such Party shall perform its obligations hereunder in accordance with all applicable Laws. 

5.2 Additional Representations and Warranties of Kinex. Kinex represents and warrants to Hanmi that: 

(a) As of the Effective Date in the Territory, (i) to Kinex’s best knowledge, there is no Third Party infringement of
any of the Kinex Intellectual Property; (ii) the Kinex Intellectual Property is in full force and effect where filed; (iii) the Kinex Patent Rights where filed are not subject to any pending or threatened re-examination, re-issue,
opposition, interference, challenge, litigation proceeding or other claim; and (iv) Kinex has not filed or prosecuted any patent applications with respect to the Kinex Intellectual Property in any of the following countries in the Territory:
Vietnam, Philippines, 

  
 34 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
Malaysia, Indonesia or Thailand; provided, however, Kinex shall cause and ensure that Hanmi is granted Data exclusivity under this Agreement in all of the abovementioned five
(5) countries and shall perform all necessary requirements in connection therewith. 
 (b) Kinex has not committed
any act, or omitted to commit any act, that may cause the Kinex Patent Rights where filed to expire prematurely or be declared invalid or unenforceable, or that stops Kinex from enforcing the Kinex Patent Rights where filed against any Third Party;

 (c) As of the Effective Date in the Territory, (i) Kinex has the sole right to use, disclose and enable Hanmi to use
and disclose (in each case under appropriate conditions of confidentiality) the Kinex Know-How; and (ii) the Kinex Intellectual Property is not subject to any encumbrance, lien, license or claim of ownership by any Third Party; 

(d) At no time during the Agreement Term shall Kinex assign, transfer, encumber, dispose of, or grant rights in, or with
respect to, the Kinex Intellectual Property in a manner that is inconsistent with the rights granted to Hanmi under this Agreement; 

(e) At no time during the Agreement Term shall Kinex, without Hanmi’s prior written consent, enter into any other
agreements regarding the Kinex Intellectual Property, Compound or the Licensed Products for Field within the Territory; 

(f) The Data and information provided to Hanmi or its Affiliates prior to the Effective Date relating to pre-clinical and
clinical studies related to Compound has been 

  
 35 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
accurate in all respects and Kinex has made no misrepresentation or omission in connection with such Data and information. Kinex has also provided Hanmi or its Affiliates with access to complete
summaries of all adverse events known to Kinex relating to the Compound; 
 (g) The Kinex Intellectual Property listed in
Schedule 1.2 is the complete and exhaustive list of all intellectual property and proprietary rights of Kinex necessary for the Development and Commercialization of the Licensed Product. 

ARTICLE 6 
 PATENT
MATTERS 
 6.1 Ownership of Inventions. 

(a) Except as otherwise provided in and subject to the terms of this Agreement, as between the Parties: 

(i) Kinex shall have and retain all right, title and interest in or Control over, as applicable, all Intellectual Property (and
Patent Rights arising thereunder) (i) existing, owned or Controlled by it on the Effective Date, subject to the licenses and other rights for the specified Territory granted to Hanmi under this Agreement both within and outside the Territory
and (ii) which is discovered, made, first conceived, reduced to practice or generated under this Agreement both within and outside the Territory as a result of Development or otherwise during the Agreement Term solely by Kinex employees,
agents, or other persons acting under or pursuant to its authority. 

  
 36 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (ii) Hanmi shall have and retain all right, title and interest in or Control
over all Intellectual Property (and Patent Rights arising thereunder) which is discovered, made, first conceived, reduced to practice or generated under this Agreement both within and outside the Territory as a result of Development or otherwise
during the Agreement Term, solely by Hanmi’s employees, agents, or other persons acting under or pursuant to its authority. 

(iii) Kinex and Hanmi shall jointly own all right, title and interest in or Control over all Intellectual Property (and Patent
Rights arising thereunder) which is discovered, made, first conceived, reduced to practice or generated under this Agreement in the Territory as a result of Development or otherwise during the Agreement Term jointly by Kinex and Hanmi employees,
agents, or other persons acting under or pursuant to their authority (“Jointly Owned Intellectual Property”). With respect to Jointly Owned Intellectual Property, both Parties shall have the right to use such Intellectual Property
within the Territory subject to the terms of this Agreement. Kinex shall have the sole right to use the Jointly Owned Intellectual Property in all countries outside the Territory without accounting or payment to Hanmi. For the avoidance of doubt,
the right, title and interest of a Party in, or control of, the Jointly Owned Intellectual Property shall survive the termination and expiration of this Agreement. 

(b) Employees and Agents. Each of Kinex and Hanmi shall require all of its and its Affiliates’ employees to assign
all inventions and corresponding patent applications that are discovered, made, first conceived, reduced to practice or generated by such employees during the Agreement Term to Kinex and/or Hanmi according to the

  
 37 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
ownership principles described in Section 6.1(a) and subject to the laws of the country of employment. Each Party shall use Commercially Reasonable Efforts to require any Third Parties
working on the Phase I Clinical Study or any Development under the Agreement or who receive materials relating to Licensed Product or Know-How from a Party, to assign or grant a sublicenseable exclusive license on a fully paid-up, royalty-free basis
to all inventions and corresponding Patent Rights that are developed, made or conceived by such Third Parties during the Agreement Term to Kinex and/or Hanmi according to the ownership principles described in Section 6.1(a). 

6.2 Maintenance and Prosecution. 

(a) Kinex Patent Rights. Kinex shall have the first right to file, prosecute and maintain the Kinex Patent Rights in
Kinex’s name, by retaining patent counsel selected by Kinex and shall be responsible for the payment of all costs and fees relating to patent prosecution and maintenance. As of the Effective Date, the Kinex Patent Rights do not include any
filings with respect to the countries of Vietnam, Philippines, Malaysia, Indonesia and Thailand. Kinex shall also have the first right to file, prosecute and maintain all Jointly Owned Intellectual Property in all countries outside the Territory.
Kinex agrees to keep Hanmi informed of the course of patent prosecution, application or other proceedings in the Territory. 

(b) Hanmi Patent Rights. Hanmi shall have the first right to file, prosecute and maintain the Hanmi Patent Rights in
Hanmi’s name, by retaining patent counsel selected by Hanmi and shall be responsible for the payment of all costs and fees relating to patent prosecution and maintenance. Hanmi agrees to keep Kinex informed of the

  
 38 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
course of patent prosecution, application or other proceedings and to furnish Kinex, per its request, with copies of office actions received by Hanmi from the United States Patent and Trademark
Office or other Regulatory Authority outside the Territory concerning Hanmi Patent Rights. Hanmi shall also have the first right to file, prosecute and maintain all Jointly Owned Intellectual Property in all countries in the Territory. Hanmi hereby
grants a right of first refusal to Kinex for any Hanmi Patent Rights for which Hanmi intends to grant any right or license outside the Territory. Hanmi shall provide Kinex with written notice of the terms on which Hanmi proposes to license such
Hanmi Patent Rights outside the Territory, and Kinex shall have ninety (90) days from the date of receipt of such written notice to send a written reply to Hanmi indicating its desire to license such Hanmi Patent Rights on the terms contained
in Hanmi’s written notice. If Kinex does not respond within the ninety (90) days, Hanmi shall be free to license such Hanmi Patent Rights to third parties outside the Territory on the terms and conditions contained in the written notice
sent to Kinex. 
 (c) The responsible Party under this Section 6.2 shall solicit the other Party’s review of the
nature and text of any patent applications within the Territory and important prosecution matters related thereto in reasonably sufficient time prior to the filing thereof, and the responsible Party shall take into account the other Party’s
reasonable comments related thereto. Each Party shall execute all documents and take all actions as are reasonably requested by the other Party with respect to any filings and registrations. 

  
 39 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 6.3 Third Party Infringement. 

(a) Each Party shall promptly give the other Party notice of any actual or suspected infringement by a Third Party in the
Territory of any patent included in the Kinex Patent Rights relating to the Licensed Product or Jointly Owned Intellectual Property (collectively, the “Parties’ Patent Rights”), which comes to such Party’s attention. In
addition, Hanmi shall give Kinex notice of any actual or suspected infringement which comes to its attention by a Third Party outside the Territory of any patent included in the Kinex Patent Rights relating to the Licensed Product or the Jointly
Owned Intellectual Property. The Parties shall thereafter consult and cooperate to determine a course of action, including the commencement of legal action. 

(b) Kinex shall have the first right to initiate and prosecute such legal action in the Territory at its own expense and in the
name of Kinex and/or Hanmi, or to control the defense of any declaratory judgment action in the Territory relating to the Parties’ Patent Rights, and Kinex shall provide Hanmi with reasonable notice of any such action it commences and keep
Hanmi reasonably informed of any significant developments in such action. Hanmi shall render, at its expense, all assistance reasonably requested in connection with any action taken by Kinex or to prevent such infringement (including reasonable
attorneys’ fees). However, the control of such action, including whether to initiate any legal proceeding and/or the settlement thereof, shall be under the control of Kinex; provided that Kinex shall not settle any such claim or
proceeding in a manner that adversely affects Hanmi’s rights under this Agreement or which results in any monetary payment by or financial loss to Hanmi, without Hanmi’s prior written consent, which consent shall not be unreasonably
withheld. 

  
 40 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (c) If Kinex elects not to initiate and prosecute an infringement or defend a
declaratory judgment action in any country in the Territory as provided in Section 6.3(b) within sixty (60) days after having become aware of such potential infringement, then Hanmi may elect, which election shall be subject to the prior
written consent of Kinex to take such action that is reasonably necessary and appropriate to terminate or prevent such infringement, including instituting an infringement proceeding, provided, however, that Hanmi shall not enter into
any settlement or compromise of any claim relating to the Parties’ Patent Rights licensed hereunder or which results in any material monetary payment by or financial loss to Kinex, without Kinex’s prior written consent, which consent shall
not be unreasonably withheld. 
 (d) Kinex shall have the sole right to initiate and prosecute any legal action outside the
Territory with respect to the Kinex Patent Rights relating to the Licensed Product, or the Jointly Owned Intellectual Property at its own expense and in the name of Kinex and/or Hanmi, or to control the defense of any declaratory judgment action
outside the Territory relating to such Patent Rights. However, the control of such action, including whether to initiate any legal proceeding and/or the settlement thereof, shall solely be under the control of Kinex. 

  
 41 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (e) For any legal action or defense contemplated by this Section 6.3, in
the event that any Party is unable to initiate, prosecute, or defend such action solely in its own name, the other Party will join such action voluntarily and will execute all documents necessary for the Party to prosecute, defend and maintain such
action. In connection with any such action, the Parties will cooperate fully and will provide each other with any information or assistance that either reasonably may request. Any recovery or award obtained by either Party as a result of any such
action or settlement shall be shared as follows: 
 (i) the Party that initiated and prosecuted, or maintained the defense
of, the action shall recoup all of its costs and expenses (including reasonable attorneys’ fees) incurred in connection with the action, whether the recovery is by settlement or otherwise; 

(ii) the other Party then shall, to the extent possible, recover its reasonably documented costs and expenses (including
reasonable outside attorneys’ fees) incurred in connection with the action; and 
 (iii) regardless of the Party
initiating the action, each Party shall be entitle to fifty percent (50%) of the remaining recovery amount attributable to the Territory. 

6.4 Third Party Intellectual Property. 

(a) In the event that a Party becomes aware of any claim that the practice by either Party of Know-How or Patent Rights or
manufacture, import, use or sale of Licensed Product hereunder infringes the intellectual property rights of any Third Party in the Territory, such Party shall promptly notify the other Party. The Parties shall thereafter discuss the situation, and
to the extent reasonably necessary, attempt to agree on a course of action. 

  
 42 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (b) If within ten (10) Business Days the Parties fail to agree upon an
appropriate course of action in the Territory, Hanmi shall have the first right, but not the obligation, to defend any action in the Territory related to the intellectual property rights of any Third Party or to initiate and prosecute legal action
in the Territory related to the intellectual property rights of any Third Party in the name of Hanmi and/or Kinex. Hanmi shall keep Kinex reasonably informed as to the progress of any such action. Kinex shall render, all assistance reasonably
requested in connection with any action taken by Hanmi. However, the control of such action, including whether to initiate any legal proceeding and/or the settlement thereof, shall solely be under the control of Hanmi; provided that
Hanmi shall not settle any such claim or proceeding in a manner that materially adversely affects Kinex’s rights under this Agreement or which results in any material monetary payment by or financial loss to Kinex, without Kinex’s written
consent, which consent shall not be unreasonably withheld. Kinex shall pay for all costs and expenses incurred by Hanmi in such defense. In addition, Kinex shall pay all damages awarded or settlement payments made (including future royalty or
similar payments) to such Third Party. 
 (c) If Hanmi elects not to defend an infringement action in any country in the
Territory as provided in Section 6.4(b), and Kinex elects to do so, the cost of any agreed-upon course of action, including the costs of any legal action commenced or any infringement action defended,
shall be borne solely by Kinex, provided, however, that Kinex shall not enter into any settlement or compromise of any claim which results in any financial loss to Hanmi without the prior written consent of Hanmi, which consent shall
not be unreasonably withheld, and Kinex shall pay all damages awarded or 

  
 43 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
settlement payments made (including future royalty or similar payments) to such Third Party. For any such legal action or defense, in the event that any Party is unable to initiate, prosecute, or
defend such action solely in its own name, the other Party will join such action voluntarily and will execute all documents necessary for the Party to prosecute, defend and maintain such action. In connection with any such action, the Parties will
cooperate fully and will provide each other with any information or assistance that either reasonably may request and all costs incurred in relation to such action shall be borne solely by Kinex. 

(d) Kinex shall have the sole right, but not the obligation to defend any action related to the intellectual property rights
outside the Territory of any Third Party or to initiate and prosecute legal action outside the Territory related to the intellectual property rights of any Third Party in the name of Hanmi and/or Kinex. Hanmi shall render, at Kinex’s expense,
all assistance reasonably requested in connection with any action taken by Kinex. However, the control of such action, including whether to initiate any legal proceeding and/or the settlement thereof, shall solely be under the control of Kinex. 

6.5 Patent Term Extensions. The Parties shall cooperate with each other in obtaining patent term extensions or restorations or
supplemental protection certificates or their equivalents in any country in the Territory where applicable and where desired by Hanmi. Elections with respect to obtaining such extension or supplemental protection certificates shall be made in the
same manner and with the same relative priorities between the Parties as is applicable to the prosecution and maintenance of Patent Rights pursuant to Section 6.2. 

  
 44 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 6.6 Patent Marking. Hanmi shall mark, and shall require its Affiliates and
sublicensees to mark, all Licensed Products sold or distributed pursuant to this Agreement in accordance with the applicable patent statutes or regulations in the country or countries of manufacture and/or sale thereof. 

ARTICLE 7 

CONFIDENTIALITY AND PUBLICITY 

7.1 Non-Disclosure and Non-Use Obligations. All Proprietary Information disclosed by one Party to the other Party hereunder shall be
maintained in confidence and shall not be disclosed to any Third Party or used for any purpose except as expressly permitted herein without the prior written consent of the Party that disclosed the Proprietary Information to the other Party during
the term of this Agreement and for a period of ten (10) years thereafter. The foregoing non-disclosure and non-use obligations shall not apply to the extent that such Proprietary Information: 

(a) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as
documented by records; 
 (b) is or becomes properly in the public domain or knowledge without breach by either Party; 

(c) is subsequently disclosed to a receiving Party by a Third Party who may lawfully do so and is not under an obligation of
confidentiality to the disclosing Party; or 
 (d) is developed by the receiving Party independently of Proprietary
Information received from the disclosing Party, as documented by records. 

  
 45 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 7.2 Permitted Disclosure of Proprietary Information. Notwithstanding Section 7.1,
a Party receiving Proprietary Information of another Party may disclose such Proprietary Information: 
 (a) to governmental
or other regulatory agencies in order to obtain patents pursuant to this Agreement, or to gain approval to conduct Clinical Studies or to market Licensed Product, but such disclosure may be only to the extent reasonably necessary to obtain such
patents or authorizations and in accordance with the terms of this Agreement or as otherwise requested by the Regulatory Authorities; 

(b) by Hanmi to its agents, consultants, sublicensees or Affiliates in connection with the Development or Commercialization, or
to otherwise enable Hanmi to fulfill its obligations and responsibilities under this Agreement, on the condition that such entities agree to be bound by confidentiality obligations consistent with this Agreement; or 

(c) if required to be disclosed by law or court order; provided that notice is promptly delivered to the
non-disclosing Party in order to provide an opportunity to challenge or limit the disclosure obligations. 
 (d) Certain
Disclosures. Except as set forth in this Agreement or as required by law, neither Party shall make any press release or other public announcement or other public disclosure to a Third Party concerning the existence of or terms of this Agreement,
the subject matter of this Agreement or the activities contemplated hereunder, without the prior written consent of the other Party, which consent shall include agreement upon the 

  
 46 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
nature and text of such release, announcement, or other disclosure, and shall not be unreasonably withheld or delayed. Each Party agrees to provide to the other Party a copy of any such press
release or other public announcement or disclosure as soon as reasonably practicable under the circumstances prior to its scheduled release. Each Party shall have the right to expeditiously (but in any event within forty eight
(48) hours) review and recommend changes to any such press release or other public announcement or disclosure; provided, however, that such right of review and recommendation shall only apply for the first time that specific
information is to be disclosed, and shall not apply to the subsequent disclosure of substantially similar information that has previously been disclosed unless there have been material developments relating to Licensed Product since the date of the
previous disclosure; provided, further, that each Party shall provide to the other Party reasonable advance notice of any such subsequent disclosure. Without limiting the generality of any of the foregoing, it is understood that the
Parties or their Affiliates may make disclosure of this Agreement and the terms hereof in accordance with the rules and regulations of the SEC, other governmental authority, or securities exchange, may file this Agreement as an exhibit to any filing
with the SEC, other governmental authority, or securities exchange, and may distribute any such filing in the ordinary course of its business; provided, further, that to the maximum extent allowable by the rules and regulations of the
SEC, other governmental authority, or securities exchange, and except as required by applicable Laws, Kinex and Hanmi shall seek to redact any confidential information set forth in such filings, and each Party shall provide a draft of the redacted
version of this Agreement to the other Party no less than five (5) Business Days prior to filing with the SEC, other governmental authority, or securities exchange, and give reasonable consideration to the other Party’s comments regarding
any proposed redaction. 

  
 47 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 7.3 Publications. Hanmi shall not submit for written or oral publication any
manuscript, abstract or the like relating to the Compound or Licensed Product, without the prior approval or written request of Kinex. If Hanmi desires to submit such publication, it shall first deliver to Kinex, for Kinex’s prior written
consent, the proposed publication or an outline of the oral disclosure at least sixty (60) days prior to planned submission or presentation. 

7.4 Publicity. Except as otherwise provided in this Agreement or required by law or regulation, no Party will originate any news
release or other public announcement, written or oral, whether in the public press, stockholders’ reports or otherwise, relating to this Agreement or to any sublicense under this Agreement, or to the performance under this Agreement or under
any sublicense under this Agreement, without the prior written approval of the other Party, which approval will not be unreasonably withheld or delayed; provided that the foregoing shall not restrict disclosures made in connection with
any filing of information or materials with a stock exchange or the SEC or any stockholders’ letter to private investors. 
 ARTICLE
8 
 TERM AND TERMINATION 

8.1 Term and Expiration. This Agreement shall be binding on the Parties as of the Effective Date. Thereafter, unless terminated earlier
pursuant to Section 8.2 below, this Agreement shall extend for a period which may expire on a country by country basis upon the earliest to occur of either (i) the expiration of the Kinex Patent Rights or (ii) invalidation of the
Kinex Patent Right (the “Agreement Term”). Notwithstanding the foregoing, after the 

  
 48 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
occurrence of (i) or (ii) above, the Agreement Term shall automatically be extended for consecutive one (1) year periods subject to the same terms and conditions set forth herein
(unless agreed otherwise) unless either Party gives written notice of its intention not to extend the Agreement term: (i) at least ninety (90) days prior to the expiration date of the Kinex Patent Rights; or (ii) as soon as
practically possible in the case of an invalidation claim; and (iii) at least ninety (90) days prior to the then current expiration date of the Agreement thereafter. 

8.2 Early Termination of Agreement Term. 

(a) Termination by Agreement. This Agreement may be terminated in whole or in part upon mutual written agreement of the
Parties. 
 (b) Termination by Hanmi. Hanmi may terminate in whole or in part this Agreement in its sole discretion
upon not less than six (6) months prior written notice of termination provided anytime after the Effective Date (provided, however, that no such termination shall be effective until the Completion of any then Ongoing Clinical
Studies). The cost involved during the six (6) months on top of completing the Ongoing Clinical Studies will also be borne by Hanmi. In addition, if any milestone is met per the Clinical Studies prior to the final termination date, Hanmi will
also be responsible for the milestone payment. 

  
 49 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (c) Termination by Either Party. Either Party may, without prejudice
to any other remedies available to it under this Agreement or at law or in equity, terminate this Agreement prior to expiration of the Agreement Term in the event that any of the following occurs: 

(i) The other Party (as used in this subsection, the “Breaching Party”) shall have materially breached or
defaulted in the performance of any of its material obligations hereunder (including a breach of the representations and warranties set forth in this Agreement), and has not cured such breach within (i) thirty (30) days after notice of
such breach is provided to the Breaching Party in case the breach is a non-payment of any amount due under this Agreement that is not being disputed in good faith (which shall be deemed a material breach of a material obligation) and (ii) sixty
(60) days after notice of such breach is provided to the Breaching Party for other cases of breach (or, if such default cannot be cured within such sixty (60) day period, if the Breaching Party does not commence and diligently continue
actions to cure such default during such sixty (60) day period). The termination shall become effective at the end of the (i) thirty (30) day period in case the breach is a non-payment of any amount due under this Agreement
that is not being disputed in good faith if the Breaching Party has not cured such breach by such date, or (ii) for other cases of breach, sixty (60) day period unless (a) the Breaching Party cures such breach during such sixty
(60) day period, or (b) if such breach is not susceptible to cure within such sixty (60) day period, the Breaching Party has commenced and is diligently pursuing a cure (unless such breach, by its nature, is incurable, in which case
the Agreement may not be terminated unless the Breaching Party fails to use its best commercially reasonable efforts to prevent a similar subsequent breach). The right of either Kinex or Hanmi to terminate this Agreement as provided in this
Section 8.2(c)(i) shall not be affected in any way by such Party’s waiver or failure to take action with respect to any previous breach or default. 

  
 50 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (ii) An administrator is appointed in respect of any of the property or
assets of the other Party. 
 (iii) The other Party stops or suspends payment of all or a class of its debts, becomes
insolvent or sells or parts with possession of the whole or a major part of its assets or major undertaking. 
 (iv) An
application or order is made, proceedings are commenced, a resolution is passed or proposed in a notice of meeting or an application to a court or other steps are taken (other than frivolous or vexatious applications, proceedings, notice or steps)
for the winding up or dissolution of the other Party or for it to enter an arrangement, compromise or composition with or assignment for the benefit of its creditors, a class of them or any of them. 

(v) The Parties agree in writing to terminate this Agreement. 

(vi) Hanmi may terminate this Agreement with immediate effect by providing written notice to the purchaser in case (i) a
competitor of Hanmi should obtain any ownership interest in Kinex and (ii) such transfer of ownership to a competitor of Hanmi should affect adversely any right of Hanmi under this Agreement, regardless of whether or not a change of control has
occurred. 
 8.3 Effect of Expiration or Termination; Survival. 

(a) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such
expiration or termination, including all accrued 

  
 51 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
payment obligations arising under Article 4 hereof. In addition to any other provisions of this Agreement which by their terms continue after the expiration of this Agreement, the provisions
of Articles 3.3(g). 6, 7, 9 and 10 shall survive the expiration or termination of this Agreement and shall continue in effect after the date of expiration or termination for the longer of (i) five (5) years or (ii) the respective
periods specified therein. Any expiration or early termination of this Agreement shall be without prejudice to the rights of any Party against the other accrued or accruing under this Agreement prior to termination. Except as expressly set forth
herein, the rights to terminate as set forth herein shall be in addition to all other rights and remedies available under this Agreement, at law, or in equity, or otherwise. 

(b) Payments of amounts owing to Kinex under this Agreement as of its expiration or termination shall be due and payable either
(i) to the extent such amounts can be calculated and a fixed sum determined at the time of expiration or termination of this Agreement, thirty (30) days after the date of such expiration or termination, or (ii) to the extent such
amounts cannot be calculated and a fixed sum determined at the time of expiration or termination of this Agreement, thirty (30) days after the date at which such amounts can be calculated and a fixed sum is mutually determined. 

(c) Subject to the payment of all amounts required hereunder, Hanmi and its Affiliates shall have the right to sell or
otherwise dispose of the stock of any Licensed Product subject to this Agreement on hand or in process of manufacture as of the expiration or termination of this Agreement. Within thirty (30) days after the effective date of termination or
expiration of this Agreement, Hanmi shall notify Kinex of the 

  
 52 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
amount of Licensed Product Hanmi, its Affiliates and sublicensees then have on hand or in the process of manufacture and shall have the right to sell in the Territory (except with respect to any
country in the Territory in which Licensed Product has been withdrawn or there is no Regulatory Approval), its remaining stock of Licensed Product until all of it is sold; provided, however, the terms and conditions of this Agreement
shall apply to such Licensed Product so sold. Kinex hereby grants a non-exclusive license to Hanmi as necessary to sell such Licensed Product in the Territory, subject to payment of all related amounts due under this Agreement. Any remaining
quantities of Licensed Product not sold, at Hanmi’s election, may be (i) destroyed by Hanmi at Hanmi’s cost, (ii) sold to Kinex at Hanmi’s procurement cost for such Licensed Product, or (iii) sold to customers in the
Territory. 
 (d) Upon the termination or expiration of this Agreement, the following shall also be applicable: (i) at
Kinex’s request, Hanmi shall promptly transfer and return to Kinex copies of all Data, reports, records and materials in Hanmi’s possession or control that relate to Compound or Licensed Products and return to Kinex all relevant records
and materials in Hanmi’s possession or control containing Proprietary Information of Kinex (provided that Hanmi may keep one copy of such Proprietary Information of Kinex for archival purposes only); (ii) Hanmi shall transfer
to Kinex ownership of any INDs, Regulatory Approvals, Drug Approval Applications and any other regulatory filings or submissions made or filed for Licensed Product by Hanmi or its designees; and (iii) Kinex shall promptly return to Hanmi all
relevant records and materials in Kinex’s possession or control containing Proprietary Information of Hanmi (provided that, Kinex may keep one copy of such Proprietary Information of Hanmi for archival purposes only). 

  
 53 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 ARTICLE 9 

INDEMNIFICATION AND INSURANCE 

9.1 Indemnity. For purposes of this Article 9, “Kinex Indemnified Parties” refers to Kinex, its Affiliates and
the officers, directors, employees, shareholders, agents and successors and assigns of Kinex and its Affiliates, and “Hanmi Indemnified Parties” refers to Hanmi, its Affiliates and officers, directors, employees, shareholders,
agents and successors and assigns of Hanmi and its Affiliates. 
 9.2 Hanmi Indemnification. Hanmi shall defend the Kinex Indemnified
Parties from and against all suits, claims, actions, demands, complaints, lawsuits or other proceedings, (collectively, “Claims”), that are brought by a Third Party, and shall indemnify and hold harmless to the fullest extent
permitted by law the Kinex Indemnified Parties from and against any and all Losses, that arise out of or are attributable to, (i) Hanmi’s gross negligence, recklessness or willful misconduct in exercising or performing any of its rights or
obligations under this Agreement; or (ii) a material breach by Hanmi of any of its obligations, representations, warranties or covenants under this Agreement; provided, however, that Hanmi shall not be obligated under this
Section 9.2, to the extent it is shown by evidence acceptable in a court of law having jurisdiction over the subject matter and meeting the appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing on
the part of Kinex. 

  
 54 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 9.3 Kinex Indemnification. Kinex shall defend the Hanmi Indemnified Parties from and
against all Claims, in each case that are brought by a Third Party, and shall indemnify and hold harmless to the fullest extent permitted by law the Hanmi Indemnified Parties from and against any and all Losses that arise out of such Claims that are
attributable to, (i) Kinex’s gross negligence, recklessness or willful misconduct in exercising or performing any of its rights or obligations under this Agreement; or (ii) a material breach by Kinex of any of its obligations,
representations, warranties or covenants under this Agreement; provided, however, that Kinex shall not be obligated under this Section 9.3, to the extent it is shown by evidence acceptable in a court of law having jurisdiction
over the subject matter and meeting the appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing on the part of Hanmi. 

9.4 Indemnification Procedure. 

(a) Each Party shall promptly notify the other Party in writing of any Claim. Concurrent with the provision of notice pursuant
to this Section 9.4(a), the Indemnified Party shall provide to the other Party copies of any complaint, summons, subpoena or other court filings or correspondence related to such Claim and will give such other information with respect thereto
as the other Party shall reasonably request. The Indemnifying Party and Indemnified Party shall meet to discuss how to respond to such Claim. Failure to provide prompt notice shall not relieve any Party of the duty to defend or indemnify unless such
failure materially prejudices the defense of any matter. Each Party agrees that it will take reasonable steps to minimize the burdens of the litigation on witnesses and on the ongoing business of the Indemnified Parties including making reasonable
accommodations to witnesses’ schedules when possible and seeking appropriate protective orders limiting the duration and/or location of depositions. 

  
 55 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (b) Should either Party dispute that any Claim or portion of a Claim
(“Disputed Claim”) of which it receives notice pursuant to Section 9.4(a), is an indemnified Claim, it shall so notify the other Party providing written notice in sufficient time to permit such other Party to retain counsel and
timely appear, answer and/or move in any such action. In such event, such other Party shall defend against such Claim; provided, however, that such other Party shall not settle any Claim which it contends is an indemnified Claim
without providing the Indemnifying Party ten (10) Business Days’ notice prior to any such settlement and an opportunity to assume the defense and indemnification of such Claim pursuant to this Agreement. If it is determined that a Disputed
Claim is subject to indemnification, the Indemnifying Party will reimburse the costs and expenses, including reasonable attorneys’ fees, of the Indemnified Party. 

9.5 Settlement of Indemnified Claims. The Indemnifying Party under Sections 9.2 or 9.3, as applicable, shall have the sole
authority to settle any Indemnified Claim without the consent of the other Party; provided, however, that an Indemnifying Party shall not, without the written consent of the other Party, as part of any settlement or compromise
(i) admit to liability on the part of the other Party; (ii) agree to an injunction against the other Party; or (iii) settle any matter in a manner that separately apportions fault to the other Party. The Parties further agree that as
part of the settlement of any Indemnified Claim, an Indemnifying Party shall obtain a full, complete and unconditional release from the claimant on behalf of the Indemnified Parties. 

  
 56 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 9.6 Insurance. 

(a) Hanmi shall maintain in the Territory, commencing as of the Effective Date, commercial general liability insurance
(including coverage for product liability, contractual liability, bodily injury, property damage and personal injury), in form and substance reasonably satisfactory to Kinex, with minimum limits of $5,000,000 per occurrence or, in case of Clinical
Studies, $5,000,000 per occurrence during the period when such Clinical Studies are being conducted (the “Insurance”). If such Insurance is written on a claims-made form, it shall continue for three (3) years following
termination of this Agreement. The Insurance shall have retroactive date to or coinciding with the Effective Date. Notwithstanding the foregoing, Hanmi may satisfy the foregoing obligation with respect to the Insurance through self-insurance. 

(b) Such Insurance shall insure against all liability arising out of the manufacture, use, sale, distribution, or marketing of
Licensed Product in and for the Territory. During the Agreement Term, Hanmi shall not permit such Insurance to be reduced, expired, materially amended or canceled during the period of the Insurance and/or the Agreement without reasonable prior
written notice that shall be sent by registered mail to Kinex. Upon request Hanmi shall provide certificates of insurance to Kinex evidencing the coverage specified herein. 

(c) Except as expressly stated herein, a Party’s liability to the other is in no way limited to the extent of the
Party’s insurance coverage. 
 (d) The Insurance shall contain an explicit clause, stating that each Party and its
insurer waive their rights of subrogation against the other Party and its directors, employees and/or any one on its behalf with respect to the Insurance. Such waiver shall not apply in the event of a malicious act. 

  
 57 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 (e) The Insurance shall be primary to any other insurance maintained by each
Party and each Party hereby waives any claim or demand as to participation in any such other insurance. 
 (f) The Insurance
shall be valid in any location worldwide regarding the activities performed by each Party hereunder (including worldwide jurisdictions) for any destination or lawsuit which will be served against the other Party. 

9.7 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL,
INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT
LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER THIS ARTICLE. 

  
 58 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 ARTICLE 10 

MISCELLANEOUS 
 10.1
Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached the Agreement for failure or delay in fulfilling or performing any term of the Agreement during the period
of time when such failure or delay is caused by or results from events beyond the reasonable control of a Party, including fire, flood, earthquake, explosion, storm, blockage, embargo, war, acts of war (whether war be declared or not), terrorism,
insurrection, riot, civil commotion, strike, lockout or other labor disturbance, failure of public utilities or common carriers, act of God or act, omission or delay in acting by any governmental authority or the other Party. The affected Party
shall notify the other Party of such force majeure circumstances as soon as reasonably practicable. 
 10.2 Assignment. The Agreement
may not be assigned or otherwise transferred without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement to an Affiliate or in connection with the transfer or sale of its
business or all of its assets or in the event of a merger, or consolidation upon prior written notice to the other Party only if the transferring Party warrants and ensures and the successor entity agrees to assume all (and not less than all) of the
transferring Party’s responsibilities and obligations under this Agreement. Notwithstanding, any assignment permitted under this Agreement shall not relieve the transferring Party of its responsibilities for performance of its obligations under
this Agreement as a primary obligor. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void. 

  
 59 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 10.3 Severability. In the event that any of the provisions contained in this Agreement
are held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated
provision(s) adversely affects the substantive rights of the Parties. In such event, the Parties covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative
to the term, covenant or condition of this Agreement or the application thereof that is invalid or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 

10.4 Notices. 

(a) Correspondence, reports, documentation, and any other communication in writing between the Parties in the course of
ordinary implementation of this Agreement (but not including any notice required by this Agreement) shall be in writing and delivered by hand, sent by e-mail, or by overnight express mail (e.g., FedEx) to any one (1) representative
designated by the Party which is to receive such written communication. 
 (b) Extraordinary notices and communications
(including but not limited to notices of termination, force majeure, material breach, change of address, or any other notices required by this Agreement) shall be in writing and shall be deemed to have been given when delivered in person, or
sent by overnight courier service (e.g., FedEx), postage prepaid, or by facsimile confirmed by prepaid registered or certified air mail letter or by overnight express mail (e.g., FedEx), or sent by prepaid certified or registered

  
 60 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
air mail, return receipt requested, to the following addresses of the Parties (or to such other address or addresses as may be specified from time to time in a written notice), and shall be
deemed to have been properly served to the addressee upon receipt of such written communication, to the following addresses of the Parties: 

if to Kinex to: 

KINEX PHARMACEUTICALS, LLC 

701 Ellicott Street 
 Buffalo,
New York 14203 
 Attention: Chief Executive Officer 

Fax No.: 716-849-6651 

if to Hanmi to: 

HANMI PHARMACEUTICAL LTD. 
 45
Hanmi Tower 
 BangYee-Dong SongPa-Gu Seoul 

138-724 South Korea 
 Tel:
82-2-410-8773 
 Attention: Director, Clinical Development & Licensing 

Fax No.: 82-2-410-9278 
 or to
such other address as the Party to whom notice is to be given may have furnished to the other Parties in writing in accordance herewith. Any such communication shall be deemed to have been given when delivered if personally delivered or sent by
facsimile on a Business Day, upon confirmed delivery by nationally-recognized overnight courier if so delivered, and on the third Business Day following the date of mailing if sent by registered or certified mail. 

  
 61 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 10.5 Specific Performance. Each of the Parties acknowledges and agrees that the other
Party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in all material respects or otherwise are breached. Accordingly, and notwithstanding anything herein to the contrary, each of the Parties
agrees that the other Party shalt be entitled to seek injunctive relief to prevent breaches of the provisions of this Agreement, and/or to enforce specifically this Agreement and the terms and provisions hereof, in any action instituted in any court
or tribunal having jurisdiction over the Parties and the matter, without posting any bond or other security, and that such injunctive relief shall be in addition to any other remedies to which such Party may be entitled, at law or in equity. Any
such action or proceeding shall be heard and determined in any court sitting in Singapore or other court of competent jurisdiction in the Territory, and the Parties hereto hereby irrevocably submit to the exclusive jurisdiction of such courts in any
such action or proceeding and irrevocably waive any defense of any inconvenient forum or alternative forum to the maintenance of any such action or proceeding, including any decision by such court regarding the substantive issues involved in the
underlying dispute. 
 10.6 Further Assurances. Each of the Parties shall take such further actions as shall be necessary or
desirable in order to effectuate the respective rights and obligations hereunder. 
 10.7 Applicable Law, Venue and Dispute
Resolution. This Agreement shall be governed by the laws of the State of New York. The United Nations Convention on Contracts for the International Sale of Goods shall not apply in any action, suit or proceeding arising out of

  
 62 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 
or relating to this Agreement. Except as provide in Section 10.5, with regard to actions of specific performance, all disputes which arise in connection with this Agreement and its
interpretation shall be settled in amicable way between the Parties. If the dispute cannot be settled in an amicable manner, it will be settled by arbitration to be held in Republic of Singapore in conformity with commercial arbitration rules of the
International Chamber of Commerce. The award rendered by arbitration shall be final and binding upon the Parties hereto. 
 10.8 Entire
Agreement. This Agreement, including the exhibits and schedules hereto, contains the entire understanding of the Parties with respect to the subject matter. All express or implied agreements and understandings, either oral or written, heretofore
made, including any offering letters, letters of intent, or term sheets, are expressly superseded by this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by all Parties hereto. 

10.9 Independent Contractors. It is expressly agreed that the Parties shall be independent contractors and that the relationship
between the Parties shall not constitute a partnership, joint venture or agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other
Party, without the prior consent of such other Party. 
 10.10 Waiver. The waiver by a Party hereto of any right hereunder or the
failure to perform or of a breach by another Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 

  
 63 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 10.11 Headings; References. The captions to the several Articles and Sections hereof
are not a part of the Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to an Article, Exhibit, Schedule or Section shall, unless otherwise
specifically provided, be to an Article, Exhibit, Schedule or Section of this Agreement. The words “including”, “includes” and “such as” are used in their non-limiting sense and have the same meaning as “including
without limitation” and “including but not limited to.” “Hereunder” and “hereto” means under or pursuant to any provision of this Agreement. 

10.12 Interpretation. Both Parties have had the opportunity to have this Agreement reviewed by an attorney; therefore, neither this
Agreement nor any provision hereof shall be construed against the drafter of this Agreement. 
 10.13 Counterparts. The Agreement may
be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to the Agreement transmitted by fax, by email in “portable document
format” (“pdf”) or by any other electronic means intended to preserve the original graphic and pictorial appearance of the Agreement shall have the same effect as physical delivery of the paper document bearing an original signature.

 10.14 No Third Party Beneficiaries. Except as specifically set forth herein, none of the provisions of this Agreement shall be for
the benefit of or enforceable by any Third Party, including any creditor of either Party hereto. No such Third Party shall obtain any right under any provision of this Agreement or shall by reasons of any such provision make any claim in respect of
any debt, liability or obligation (or otherwise) against either Party hereto. 

  
 64 

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth
above. 
  

			
	KINEX PHARMACEUTICALS, LLC
		
	By:	 	  

	Name:	 	Allen Barnett
	Title:	 	Chief Executive Officer
	
	HANMI PHARMACEUTICAL LTD.
		
	By:	 	  

	Name:	 	Gwan-Sun Lee
	Title:	 	President and CEO

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

			
	SCHEDULE 1.1	 	DIAGRAM OF COMPOUND
		
	SCHEDULE 1.2	 	KINEX INTELLECTUAL PROPERTY
		
	SCHEDULE 1.3	 	FORM SUMMARY REPORT

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 SCHEDULE 1.1 

DIAGRAM OF COMPOUND 
 ***

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 SCHEDULE 1.2 

KINEX INTELLECTUAL PROPERTY 

Appendix B 
 Kinex
Pharmaceuticals, LLC 
 Select KX01 (KX2-391) Patents Jan. 13, 2011 

*** 
  

											
	 Country
	 	 Serial No.
	 	 Publication /

Patent No.
	 	 Issue Date
	 	 Expiration

Date
	 	 Coverage

	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***
	***	 	***	 	***	 	***	 	***	 	***

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 EXECUTION COPY 
  

 SCHEDULE 1.3 

FORM SUMMARY REPORT 

  

	*** =	Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]